Myc (MYC proto-oncogene, bHLH transcription factor) - Rat Genome Database

Send us a Message
Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   
Search RGD Grant Resources Citing RGD About Us Contact Us
Genes Variants Community Projects QTLs Strains Markers Genome Information Ontologies Cell Lines References Download Submit Data
OntoMate (Literature Search) JBrowse (Genome Browser) Synteny Browser (VCMap) Variant Visualizer Multi-Ontology Enrichment (MOET) Gene-Ortholog Location Finder (GOLF) InterViewer (Protein-Protein Interactions) PhenoMiner (Quatitative Phenotypes) Gene Annotator OLGA (Gene List Generator) AllianceMine GViewer (Genome Viewer)
Aging & Age-Related Disease Behavioral & Substance Use Disorder Cancer & Neoplastic Disease Cardiovascular Disease Coronavirus Disease Developmental Disease Diabetes Hematologic Disease Immune & Inflammatory Disease Infectious Disease Liver Disease Neurological Disease Obesity & Metabolic Syndrome Renal Disease Respiratory Disease Sensory Organ Disease
Find Models Genetic Models Autism Models Rat PhenoMiner (Quantitative Phenotypes) Chinchilla PhenoMiner Expected Ranges (Quantitative Phenotype) PhenoMiner Term Comparison Hybrid Rat Diversity Panel Phenotypes Phenotypes in Other Animal Models Animal Husbandry Strain Medical Records Phylogenetics Strain Availability Calendar Rats 101 Submissions Photo Archive
Pathways
Rat Community Forum Directory of Rat Laboratories Video Tutorials News RGD Publications RGD Presentations Archive Nomenclature Guidelines Resource Links Laboratory Resources Employment Resources
Advanced Search (OLGA)
Gene: Myc (MYC proto-oncogene, bHLH transcription factor) Rattus norvegicus
Analyze
Symbol: Myc
Name: MYC proto-oncogene, bHLH transcription factor
RGD ID: 3130
Description: Enables DNA-binding transcription factor activity; double-stranded DNA binding activity; and sequence-specific DNA binding activity. Involved in several processes, including cellular response to ketone; cellular response to peptide hormone stimulus; and regulation of nucleobase-containing compound metabolic process. Predicted to be located in several cellular components, including euchromatin; nucleus; and rough endoplasmic reticulum. Predicted to be part of Myc-Max complex and RNA polymerase II transcription repressor complex. Predicted to be active in chromatin. Used to study artery disease (multiple); hepatocellular carcinoma; leiomyoma; osteoporosis; and prostatic hypertrophy. Biomarker of breast cancer; carcinoma (multiple); obesity; polycystic kidney disease; and prolactinoma. Human ortholog(s) of this gene implicated in several diseases, including angiosarcoma; carcinoma (multiple); demyelinating disease; hematologic cancer (multiple); and prostate cancer (multiple). Orthologous to human MYC (MYC proto-oncogene, bHLH transcription factor); PARTICIPATES IN ceramide signaling pathway; interleukin-2 signaling pathway; interleukin-6 signaling pathway; INTERACTS WITH (+)-schisandrin B; (-)-epigallocatechin 3-gallate; (R)-noradrenaline.
Type: protein-coding
RefSeq Status: REVIEWED
Previously known as: Avian myelocytomatosis viral (v-myc) oncogene homolog; c-myc; MGC105490; mMyc; myc proto-oncogene protein; myelocytomatosis oncogene; myelocytomatosis viral oncogene homolog; myelocytomatosis viral oncogene homolog (avian); proto-oncogene c-Myc; RNCMYC; transcription factor p64; v-myc avian myelocytomatosis viral oncogene homolog
RGD Orthologs
Human
Mouse
Chinchilla
Bonobo
Dog
Squirrel
Pig
Green Monkey
Naked Mole-Rat
Alliance Orthologs
More Info more info ...
Is Marker For: Strains:   W-Tg(MT2A-Myc)1Ys   W-Tg(MT2A-Myc)2Ys  
Candidate Gene For: Lnnr1 Hcas1 Ept7 Teswt1
Latest Assembly: GRCr8 - GRCr8 Assembly
Position:
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr8795,483,105 - 95,488,031 (+)NCBIGRCr8GRCr8GRCr8
GRCr8 Ensembl795,483,105 - 95,488,028 (+)EnsemblGRCr8
mRatBN7.2793,593,705 - 93,598,633 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl793,593,705 - 93,598,630 (+)EnsemblmRatBN7.2
UTH_Rnor_SHR_Utx795,416,828 - 95,421,746 (+)NCBIUTH_Rnor_SHR_UtxUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0797,619,124 - 97,624,042 (+)NCBIUTH_Rnor_SHRSP_BbbUtx_1.0UTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0797,498,652 - 97,503,571 (+)NCBIUTH_Rnor_WKY_Bbb_1.0UTH_Rnor_WKY_Bbb_1.0
Rnor_6.07102,586,313 - 102,591,240 (+)NCBIRnor_6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl7102,586,313 - 102,591,240 (+)Ensemblrn6Rnor6.0
Rnor_5.07103,157,452 - 103,162,379 (+)NCBIRnor_5.0Rnor_5.0rn5
RGSC_v3.4798,953,142 - 98,958,060 (+)NCBIRGSC_v3.4RGSC_v3.4rn4
Celera790,263,903 - 90,268,823 (+)NCBICelera
RGSC_v3.1798,987,371 - 98,992,287 (+)NCBI
Cytogenetic Map7q33NCBI
JBrowse:




Disease Annotations     Click to see Annotation Detail View
Aberrant Crypt Foci  (IDA)
acute kidney failure  (ISO)
acute lymphoblastic leukemia  (ISO)
acute myeloid leukemia  (ISO)
acute promyelocytic leukemia  (ISO)
adenocarcinoma  (ISO)
Alcoholic Liver Diseases  (ISO)
angiosarcoma  (ISO)
Animal Disease Models  (ISO)
atherosclerosis  (ISO)
autosomal dominant polycystic kidney disease  (ISO,ISS)
autosomal recessive polycystic kidney disease  (ISO)
B-lymphoblastic leukemia/lymphoma  (ISO)
breast cancer  (IEP,ISO,ISS)
Breast Neoplasms  (IDA,ISO)
Burkitt lymphoma  (ISO,ISS)
carcinoma  (ISO)
Cardiomegaly  (IDA)
Carotid Artery Injuries  (IDA,IEP,IMP)
cholesteatoma of middle ear  (ISO)
Chromosome Breakage  (ISO)
chronic lymphocytic leukemia  (ISO)
clear cell renal cell carcinoma  (ISO)
cleft lip  (ISO)
cleft palate  (ISO)
Colonic Neoplasms  (IDA,ISO)
Colorectal Neoplasms  (ISO)
coronary restenosis  (IDA)
COVID-19  (ISO)
demyelinating disease  (ISO)
Diabetic Cardiomyopathies  (IEP)
diffuse large B-cell lymphoma  (ISO)
disease of cellular proliferation  (ISO)
Disease Progression  (ISO)
Ductal Carcinoma  (ISO)
Endometrial Neoplasms  (ISO)
Esophageal Neoplasms  (IDA)
Experimental Diabetes Mellitus  (IEP)
Experimental Liver Cirrhosis  (ISO)
Experimental Liver Neoplasms  (IEP,ISO)
Experimental Mammary Neoplasms  (ISO)
glioblastoma  (ISO)
Hemorrhagic Shock  (IDA)
hepatitis C  (ISO)
hepatocellular carcinoma  (IDA,IEP,ISO,ISS)
Hodgkin's lymphoma  (ISO)
hyperparathyroidism  (ISO)
hypertrophic cardiomyopathy  (ISO)
Kidney Reperfusion Injury  (IEP)
Left Ventricular Hypertrophy  (ISO)
leiomyoma  (IDA)
liver cirrhosis  (ISO)
Liver Injury  (IEP)
Liver Neoplasms  (ISO)
lung adenocarcinoma  (ISO)
lung cancer  (ISO)
Lung Neoplasms  (ISO)
lung non-small cell carcinoma  (ISO)
Lung Reperfusion Injury  (IEP)
lung small cell carcinoma  (ISO)
medulloblastoma  (ISO)
Merkel cell carcinoma  (ISO)
myelodysplastic syndrome  (ISO)
Neoplasm Metastasis  (ISO)
Neoplastic Cell Transformation  (ISO)
nephroblastoma  (ISO)
neuroblastoma  (ISO)
neuroectodermal tumor  (ISO)
obesity  (IEP)
osteoporosis  (IDA)
osteosarcoma  (ISO)
Ovarian Neoplasms  (ISO)
pancreatic cancer  (ISO)
pancreatic carcinoma  (ISS)
papillary thyroid carcinoma  (ISO)
polycystic kidney disease  (IEP,ISO)
polycystic kidney disease 1  (ISO)
primary ovarian insufficiency  (ISO)
prolactinoma  (IEP)
prostate adenocarcinoma  (ISO)
prostate cancer  (ISO)
prostate carcinoma in situ  (ISO)
prostatic hypertrophy  (IDA)
Prostatic Neoplasms  (ISO)
pulmonary hypertension  (IDA)
renal cell carcinoma  (IEP,ISO)
renal fibrosis  (ISO)
rhabdoid cancer  (ISO)
Sporadic Papillary Renal Cell Carcinoma  (ISO)
squamous cell carcinoma  (ISO)
steatotic liver disease  (ISO)
Stomach Neoplasms  (ISO)
thyroid cancer  (ISO)
Transplant Rejection  (IMP)
trichorhinophalangeal syndrome type I  (ISO)
urinary bladder cancer  (ISO)
Uterine Cervical Neoplasms  (ISO)

Gene-Chemical Interaction Annotations     Click to see Annotation Detail View
(+)-epicatechin-3-O-gallate  (ISO)
(+)-schisandrin B  (EXP)
(-)-anisomycin  (ISO)
(-)-epigallocatechin 3-gallate  (EXP,ISO)
(-)-selegiline  (ISO)
(1->4)-beta-D-glucan  (ISO)
(20S)-ginsenoside Rg3  (ISO)
(25R)-cholest-5-ene-3beta,26-diol  (ISO)
(R)-lipoic acid  (ISO)
(R)-noradrenaline  (EXP)
(R,R,R)-alpha-tocopherol  (EXP)
(S)-colchicine  (EXP)
(S)-nicotine  (ISO)
1'-acetoxychavicol acetate  (ISO)
1,1-dichloroethene  (ISO)
1,2,4-trimethylbenzene  (EXP)
1,2-dichlorobenzene  (EXP)
1,2-dichloroethane  (ISO)
1,2-dimethylhydrazine  (ISO)
1,3-benzothiazole-2-thiol  (ISO)
1,4-dichlorobenzene  (EXP)
1,8-cineole  (ISO)
1-[(2,3,4-trimethoxyphenyl)methyl]piperazine  (ISO)
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile  (EXP)
1-chloro-2,4-dinitrobenzene  (ISO)
1-naphthyl isothiocyanate  (EXP)
1-nitropyrene  (ISO)
14-Deoxy-11,12-didehydroandrographolide  (ISO)
17alpha-ethynylestradiol  (EXP,ISO)
17beta-estradiol  (EXP,ISO)
17beta-hydroxy-5alpha-androstan-3-one  (ISO)
1D-myo-inositol 1,4,5-trisphosphate  (EXP)
2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole  (ISO)
2,2',4,4',5,5'-hexachlorobiphenyl  (ISO)
2,2',4,4'-Tetrabromodiphenyl ether  (ISO)
2,3,7,8-tetrachlorodibenzodioxine  (EXP,ISO)
2,4-D  (ISO)
2,4-dibromophenyl 2,4,5-tribromophenyl ether  (ISO)
2,4-dinitrotoluene  (EXP)
2-acetamidofluorene  (EXP)
2-butoxyethanol  (ISO)
2-hydroxy-17beta-estradiol  (ISO)
2-Hydroxy-6-(8,11,14-pentadecatrienyl)benzoic acid  (ISO)
2-hydroxypropanoic acid  (ISO)
2-methyl-2-[4-(1,2,3,4-tetrahydronaphthalen-1-yl)phenoxy]propanoic acid  (EXP)
2-nitrofluorene  (EXP)
2-nitrotoluene  (EXP)
2-palmitoylglycerol  (ISO)
26-hydroxycholesterol  (ISO)
3,3',5,5'-tetrabromobisphenol A  (ISO)
3,3'-diindolylmethane  (ISO)
3,3,4,4,5,5,6,6,7,7,8,8,9,9,10,10,10-heptadecafluoro-1-decanol  (EXP)
3-aminobenzamide  (ISO)
3-chloropropane-1,2-diol  (EXP)
3-isobutyl-1-methyl-7H-xanthine  (EXP)
3-phenylprop-2-enal  (ISO)
4,4'-diaminodiphenylmethane  (ISO)
4,4'-sulfonyldiphenol  (ISO)
4-(ethoxymethylene)-2-phenyloxazol-5-one  (ISO)
4-(N-nitrosomethylamino)-1-(3-pyridyl)butan-1-one  (EXP,ISO)
4-hydroxy-17beta-estradiol  (ISO)
4-Hydroxy-N-desmethyltamoxifen  (ISO)
4-hydroxynon-2-enal  (ISO)
4-hydroxyphenyl retinamide  (ISO)
5-aza-2'-deoxycytidine  (ISO)
5-azacytidine  (ISO)
5-bromo-2'-deoxyuridine  (ISO)
5-fluorouracil  (ISO)
5-nitroso-8-quinolinol  (ISO)
6-propyl-2-thiouracil  (EXP)
7,12-dimethyltetraphene  (ISO)
7beta-aminocephalosporanic acid  (ISO)
8-Br-cAMP  (ISO)
8-bromo-3',5'-cyclic GMP  (ISO)
abexinostat  (ISO)
acetaldehyde  (ISO)
acetohydrazide  (ISO)
acetylleucyl-leucyl-norleucinal  (ISO)
acetylsalicylic acid  (EXP,ISO)
aconitine  (EXP,ISO)
acrolein  (EXP,ISO)
acrylamide  (ISO)
actinomycin D  (EXP,ISO)
adenosine  (EXP,ISO)
Aeroplysinin 1  (ISO)
afimoxifene  (ISO)
aflatoxin B1  (EXP,ISO)
AH23848  (ISO)
alachlor  (ISO)
aldehydo-D-glucose  (EXP,ISO)
all-trans-retinoic acid  (EXP,ISO)
all-trans-retinol  (ISO)
allethrin  (ISO)
alpha-hexachlorocyclohexane  (EXP)
alpha-naphthoflavone  (EXP,ISO)
alpha-pinene  (ISO)
alpha-Zearalanol  (EXP)
aluminium atom  (ISO)
aluminium(0)  (ISO)
amifostine  (ISO)
amiodarone  (EXP)
ammonium chloride  (EXP)
ammonium hexachloroplatinate  (ISO)
amsacrine  (ISO)
andrographolide  (ISO)
androstane  (ISO)
androstane-3,17-dione  (ISO)
anthra[1,9-cd]pyrazol-6(2H)-one  (EXP,ISO)
antimycin A  (ISO)
antirheumatic drug  (ISO)
Antrocin  (ISO)
aprepitant  (ISO)
aristolochic acid A  (ISO)
aristolochic acids  (EXP)
arsenic acid  (EXP,ISO)
arsenic trichloride  (ISO)
arsenite(3-)  (EXP,ISO)
arsenous acid  (EXP,ISO)
ARV-825  (ISO)
Asimicin  (ISO)
aspartame  (ISO)
atorvastatin calcium  (ISO)
atrazine  (ISO)
Azaspiracid  (ISO)
Azoxymethane  (EXP,ISO)
bathocuproine disulfonic acid  (ISO)
benazepril  (EXP)
benzamide  (ISO)
benzene  (ISO)
benzo[a]pyrene  (EXP,ISO)
benzo[a]pyrene diol epoxide I  (ISO)
Benzo[b]fluorene  (EXP)
benzoates  (ISO)
benzoic acid  (ISO)
benzylpenicillin  (ISO)
berberine  (EXP)
beryllium difluoride  (ISO)
beryllium sulfate  (EXP)
betulin  (ISO)
betulinic acid  (ISO)
Betulonic acid  (ISO)
bicalutamide  (ISO)
bis(2-chloroethyl) sulfide  (ISO)
bis(2-ethylhexyl) phthalate  (EXP,ISO)
bisphenol A  (EXP,ISO)
bisphenol AF  (ISO)
Bisphenol B  (ISO)
bisphenol F  (ISO)
bleomycin A2  (ISO)
bleomycin A5  (ISO)
bortezomib  (ISO)
bromobenzene  (EXP)
bromochloroacetic acid  (EXP)
bromodichloromethane  (EXP,ISO)
bromoform  (ISO)
bucladesine  (ISO)
budesonide  (ISO)
bufalin  (ISO)
Bufotalin  (ISO)
busulfan  (ISO)
Butylbenzyl phthalate  (ISO)
Butylparaben  (ISO)
butyric acid  (EXP,ISO)
C.I. Natural Red 20  (ISO)
cadmium acetate  (EXP)
cadmium atom  (EXP,ISO)
cadmium dichloride  (EXP,ISO)
cadmium sulfate  (ISO)
caffeine  (EXP,ISO)
calcein am  (ISO)
calcitriol  (ISO)
calcium dichloride  (EXP)
calmidazolium  (ISO)
camptothecin  (ISO)
cannabidiol  (EXP,ISO)
capsaicin  (ISO)
captan  (ISO)
carbamazepine  (ISO)
carbofuran  (EXP,ISO)
carbon nanotube  (ISO)
carbonyl sulfide  (EXP)
carboplatin  (ISO)
carboxy-PTIO  (ISO)
carvedilol  (EXP)
catechol  (ISO)
celastrol  (ISO)
celecoxib  (ISO)
CGP 52608  (ISO)
chalcone  (ISO)
chelerythrine  (ISO)
CHIR 99021  (ISO)
chlorambucil  (ISO)
Chlorodibromomethane  (ISO)
chloroform  (EXP,ISO)
chlorohydrocarbon  (ISO)
chloropicrin  (ISO)
chlorpromazine  (ISO)
chlorpyrifos  (ISO)
Cholestane-3,5,6-triol  (EXP)
choline  (ISO)
chromium(6+)  (ISO)
ciglitazone  (ISO)
ciguatoxin CTX1B  (ISO)
cilostazol  (ISO)
Cinobufagin  (ISO)
cisplatin  (ISO)
citalopram  (EXP)
clofarabine  (ISO)
clofibrate  (EXP,ISO)
clotrimazole  (ISO)
cobalt dichloride  (ISO)
copper atom  (EXP,ISO)
copper(0)  (EXP,ISO)
cordycepin  (ISO)
coumarin  (ISO)
coumestrol  (ISO)
crocidolite asbestos  (EXP,ISO)
crocin-1  (ISO)
CU-O LINKAGE  (ISO)
Cuprizon  (EXP)
curcumin  (ISO)
cyanamide  (EXP)
cycloheximide  (EXP,ISO)
cyclosporin A  (EXP,ISO)
cyproterone acetate  (EXP)
D-glucose  (EXP,ISO)
daidzein  (ISO)
DDE  (ISO)
DDT  (EXP,ISO)
deguelin  (ISO)
deoxynivalenol  (ISO)
desferrioxamine B  (ISO)
Destruxin B  (ISO)
dexamethasone  (EXP,ISO)
dextran sulfate  (ISO)
diallyl trisulfide  (ISO)
diarsenic trioxide  (EXP,ISO)
diarylheptanoid  (ISO)
diazinon  (EXP,ISO)
dibenziodolium  (ISO)
dibenzoylmethane  (ISO)
dibromoacetic acid  (ISO)
Dibromoacetonitrile  (EXP)
Dibutyl phosphate  (ISO)
dibutyl phthalate  (EXP,ISO)
dichloroacetic acid  (ISO)
diclofenac  (EXP,ISO)
dicrotophos  (ISO)
Dictamnine  (ISO)
dieldrin  (EXP)
diethylstilbestrol  (EXP,ISO)
dihydroartemisinin  (ISO)
Dimaprit  (ISO)
dimethyl sulfoxide  (ISO)
dimethylarsinic acid  (ISO)
diminazene diaceturate  (ISO)
dinaciclib  (ISO)
diosgenin  (ISO)
dioxygen  (EXP,ISO)
diquat  (ISO)
disodium selenite  (EXP,ISO)
disulfiram  (ISO)
dorsomorphin  (ISO)
doxorubicin  (EXP,ISO)
elemental selenium  (EXP,ISO)
emodin  (EXP)
endosulfan  (ISO)
enzalutamide  (ISO)
epichlorohydrin  (ISO)
epoxiconazole  (ISO)
erlotinib hydrochloride  (ISO)
erythromycin estolate  (EXP)
escitalopram  (EXP)
estra-1,3,5(10)-triene-3,16beta-diol  (EXP)
estriol  (EXP)
ethanol  (EXP,ISO)
ethyl methanesulfonate  (ISO)
etoposide  (ISO)
eugenol  (ISO)
everolimus  (ISO)
Evodiamine  (ISO)
fenofibrate  (EXP,ISO)
fenthion  (ISO)
fipronil  (EXP)
fluoranthene  (ISO)
fluoxetine  (ISO)
flusilazole  (ISO)
flutamide  (EXP)
folic acid  (ISO)
formaldehyde  (ISO)
FR900359  (ISO)
fructose  (ISO)
fucoidan  (ISO)
fulvestrant  (EXP,ISO)
furan  (EXP,ISO)
galangin  (ISO)
gallium nitrate  (ISO)
gamma-aminobutyric acid  (EXP)
gamma-hexachlorocyclohexane  (EXP)
gamma-linolenic acid  (ISO)
gamma-tocopherol  (ISO)
gefitinib  (ISO)
gemcitabine  (ISO)
gemfibrozil  (ISO)
genistein  (ISO)
gentamycin  (EXP)
glucaric acid  (ISO)
glucose  (EXP,ISO)
glutathione  (EXP,ISO)
Glutethimide  (EXP)
glycerol  (EXP,ISO)
glycidol  (EXP)
glycine betaine  (EXP)
glyphosate  (EXP,ISO)
GSK-J4  (ISO)
guanosine  (ISO)
guggulsterone  (ISO)
GW 4064  (ISO)
GW 7647  (ISO)
harmine  (ISO)
hemin  (ISO)
heparin  (EXP,ISO)
hesperetin  (EXP)
hexachlorophene  (ISO)
hexadecanoic acid  (ISO)
hexamethylene diisocyanate  (ISO)
hexanal  (ISO)
Honokiol  (ISO)
hydrogen peroxide  (ISO)
hydroquinone  (ISO)
hydroxamic acid  (ISO)
Indeno[1,2,3-cd]pyrene  (ISO)
indirubin  (ISO)
indole-3-methanol  (EXP)
indometacin  (EXP,ISO)
Inotodiol  (EXP)
inulin  (ISO)
ionomycin  (ISO)
iron atom  (ISO)
iron(0)  (ISO)
iron(III) nitrilotriacetate  (EXP)
isoprenaline  (EXP,ISO)
ketamine  (EXP)
KT 5823  (ISO)
L-ascorbic acid  (ISO)
L-methionine  (ISO)
lead nitrate  (ISO)
leflunomide  (ISO)
letrozole  (ISO)
limonene  (EXP,ISO)
linalool  (ISO)
linuron  (EXP)
lipoic acid  (ISO)
lipopolysaccharide  (EXP,ISO)
lithium chloride  (EXP,ISO)
Lobetyolin  (ISO)
losartan  (EXP)
lupeol  (ISO)
LY294002  (ISO)
m-xylene  (EXP)
mancozeb  (EXP,ISO)
maneb  (ISO)
masoprocol  (ISO)
mebendazole  (ISO)
melatonin  (ISO)
meloxicam  (ISO)
memantine  (ISO)
menadione  (ISO)
mercury atom  (ISO)
mercury dichloride  (EXP)
mercury(0)  (ISO)
meso-tetrakis(N-methyl-4-pyridyl)porphine(4+)  (ISO)
mestranol  (EXP)
metformin  (EXP,ISO)
methamphetamine  (EXP)
methapyrilene  (EXP)
methotrexate  (ISO)
methoxyacetic acid  (ISO)
methyl methanesulfonate  (ISO)
methylarsonic acid  (ISO)
methylmercury chloride  (EXP,ISO)
methylseleninic acid  (ISO)
metoprolol  (EXP)
microcystin-LR  (ISO)
mifepristone  (ISO)
mitoxantrone  (ISO)
ML-7  (ISO)
molibresib  (ISO)
monensin A  (EXP)
mono(2-ethylhexyl) phthalate  (EXP,ISO)
myricetin  (ISO)
N(4)-hydroxycytidine  (ISO)
N(gamma)-nitro-L-arginine methyl ester  (ISO)
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine  (ISO)
N,N-bis(2-hydroxypropyl)nitrosamine  (EXP)
N,N-dimethylaniline  (ISO)
N-(6-acetamidohexyl)acetamide  (ISO)
N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide  (EXP)
N-acetyl-L-cysteine  (EXP,ISO)
N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal  (ISO)
N-butyl-N-(4-hydroxybutyl)nitrosamine  (EXP,ISO)
N-ethyl-N-nitrosourea  (ISO)
N-methyl-4-phenylpyridinium  (EXP,ISO)
N-methyl-N'-nitro-N-nitrosoguanidine  (ISO)
N-methyl-N-nitrosourea  (EXP,ISO)
N-methylnicotinate  (ISO)
N-nitrosodiethylamine  (EXP,ISO)
N-nitrosodimethylamine  (EXP)
N-nitrosomorpholine  (EXP)
N1'-[2-[[5-[(dimethylamino)methyl]-2-furanyl]methylthio]ethyl]-N1-methyl-2-nitroethene-1,1-diamine  (EXP)
nafenopin  (EXP)
naloxone  (EXP)
naphthalene  (ISO)
naphthalenes  (EXP)
nickel atom  (ISO)
nickel dichloride  (EXP,ISO)
nickel subsulfide  (ISO)
nickel sulfate  (EXP,ISO)
niclosamide  (EXP,ISO)
nicotinamide  (ISO)
nicotine  (ISO)
nifedipine  (ISO)
nirogacestat  (ISO)
nitrofurazone  (EXP)
nitroprusside  (ISO)
Nodularin  (ISO)
Nonylphenol  (EXP)
NS-398  (ISO)
o-anisidine  (ISO)
obeticholic acid  (ISO)
ochratoxin A  (EXP,ISO)
okadaic acid  (ISO)
oleanolic acid  (EXP,ISO)
oridonin  (ISO)
ortho-Aminoazotoluene  (ISO)
ouabain  (ISO)
oxaliplatin  (ISO)
oxidopamine  (EXP)
ozone  (EXP,ISO)
paclitaxel  (EXP,ISO)
palbociclib  (ISO)
panobinostat  (ISO)
paracetamol  (EXP,ISO)
paraquat  (EXP,ISO)
PD 0325901  (ISO)
Pentoxifylline  (EXP)
perfluorononanoic acid  (ISO)
perfluorooctane-1-sulfonic acid  (ISO)
perfluorooctanoic acid  (EXP,ISO)
pevonedistat  (ISO)
phenethyl isothiocyanate  (ISO)
phenformin  (EXP)
phenobarbital  (EXP,ISO)
phenol  (ISO)
phenylhydrazine  (ISO)
phenytoin  (ISO)
PhIP  (EXP,ISO)
phorbol 13-acetate 12-myristate  (ISO)
phorone  (EXP)
phosgene  (ISO)
picene  (ISO)
pinosylvin  (ISO)
piperonyl butoxide  (EXP,ISO)
pirinixic acid  (EXP,ISO)
piroxicam  (EXP)
platycodin D  (ISO)
poly(I:C)  (ISO)
ponatinib  (ISO)
potassium dichromate  (ISO)
pregnenolone 16alpha-carbonitrile  (ISO)
proanthocyanidin  (ISO)
progesterone  (ISO)
promegestone  (ISO)
promethazine  (EXP)
propiconazole  (ISO)
propylparaben  (ISO)
prostaglandin D2  (EXP)
prostaglandin E2  (EXP,ISO)
pterostilbene  (ISO)
puerarin  (ISO)
putrescine  (EXP)
pyrrolidine dithiocarbamate  (ISO)
pyrvinium  (ISO)
quartz  (ISO)
quercetin  (ISO)
quinacrine  (ISO)
quinapril hydrochloride  (EXP)
quinidine  (EXP)
quinolone  (ISO)
quizartinib  (ISO)
rac-lactic acid  (ISO)
raloxifene  (ISO)
ranitidine  (EXP)
reactive oxygen species  (ISO)
Rebamipide  (EXP)
regorafenib  (ISO)
reserpine  (ISO)
resveratrol  (EXP,ISO)
ribavirin  (ISO)
riboflavin  (ISO)
ritonavir  (ISO)
rotenone  (EXP,ISO)
royal jelly  (EXP,ISO)
ruxolitinib  (ISO)
S-(1,2-dichlorovinyl)-L-cysteine  (ISO)
S-butyl-DL-homocysteine (S,R)-sulfoximine  (EXP)
saccharin  (ISO)
Salinomycin  (ISO)
salvianolic acid B  (ISO)
sapanisertib  (ISO)
SB 431542  (ISO)
Securinine  (ISO)
selenium atom  (EXP,ISO)
selinexor  (ISO)
selumetinib  (ISO)
serpentine asbestos  (ISO)
sertraline  (ISO)
sevoflurane  (ISO)
Shikonin  (ISO)
sildenafil citrate  (EXP)
silibinin  (ISO)
silicon dioxide  (ISO)
sirolimus  (ISO)
sirtinol  (EXP)
sodium arsenite  (EXP,ISO)
sodium chromate  (ISO)
sodium dichromate  (EXP,ISO)
sodium dodecyl sulfate  (EXP)
Soman  (EXP,ISO)
sorafenib  (ISO)
staurosporine  (ISO)
styrene oxide  (ISO)
SU6656  (ISO)
succimer  (ISO)
succinic acid  (ISO)
sulfates  (ISO)
sulforaphane  (ISO)
sulfur dioxide  (EXP)
sulindac  (EXP,ISO)
sunitinib  (ISO)
T-2 toxin  (ISO)
tacrolimus hydrate  (EXP,ISO)
tadalafil  (EXP)
taiwanin C  (ISO)
tamibarotene  (ISO)
tamoxifen  (EXP,ISO)
Tanshinone I  (ISO)
taurocholic acid  (ISO)
tebufenpyrad  (ISO)
temozolomide  (ISO)
teniposide  (ISO)
terbufos  (ISO)
terbutylazine  (ISO)
tert-butyl hydroperoxide  (ISO)
testosterone  (ISO)
Tetrachlorobisphenol A  (EXP,ISO)
tetrachloromethane  (EXP,ISO)
tetracycline  (EXP)
thapsigargin  (ISO)
theaflavin  (ISO)
theophylline  (EXP,ISO)
thiamine(1+) chloride  (EXP)
thifluzamide  (ISO)
thioacetamide  (EXP)
thiophenes  (ISO)
thiram  (ISO)
thymidine  (ISO)
thymol  (ISO)
thymol sulfate(1-)  (ISO)
thymoquinone  (ISO)
tiazofurine  (ISO)
titanium dioxide  (ISO)
tocopherol  (ISO)
toxaphene  (ISO)
trametinib  (ISO)
trans-chalcone  (ISO)
trans-pinosylvin  (ISO)
Tributyltin oxide  (ISO)
trichloroacetic acid  (ISO)
trichloroethene  (EXP,ISO)
trichostatin A  (ISO)
triclosan  (ISO)
trimellitic anhydride  (ISO)
triphenyl phosphate  (EXP,ISO)
Triptolide  (EXP,ISO)
troglitazone  (ISO)
trovafloxacin  (ISO)
tubastatin A  (ISO)
tunicamycin  (ISO)
undecane  (EXP)
urethane  (ISO)
uridine  (ISO)
valproic acid  (EXP,ISO)
vemurafenib  (ISO)
venetoclax  (ISO)
vincaleukoblastine  (EXP,ISO)
vincristine  (EXP,ISO)
vinyl carbamate  (ISO)
vorinostat  (EXP,ISO)
WIN 55212-2  (ISO)
wortmannin  (ISO)
WR-1065  (ISO)
xanthohumol  (EXP)
XAV939  (ISO)
zearalenone  (ISO)
zerumbone  (ISO)
zinc atom  (ISO)
zinc(0)  (ISO)

Gene Ontology Annotations     Click to see Annotation Detail View

Biological Process
acinar cell proliferation  (ISO)
amino acid transport  (IMP)
B cell apoptotic process  (ISO)
branching involved in ureteric bud morphogenesis  (ISO,ISS)
cell population proliferation  (ISO)
cellular response to angiotensin  (IEP)
cellular response to arsenite(3-)  (IEP)
cellular response to carbohydrate stimulus  (IEP)
cellular response to cycloheximide  (IEP)
cellular response to cytokine stimulus  (IEP)
cellular response to dimethyl sulfoxide  (IEP)
cellular response to endothelin  (IEP)
cellular response to epidermal growth factor stimulus  (IEP)
cellular response to estrogen stimulus  (IEP)
cellular response to fibroblast growth factor stimulus  (IEP)
cellular response to glucose stimulus  (IEP)
cellular response to growth hormone stimulus  (IEP)
cellular response to hydrostatic pressure  (IEP)
cellular response to hypoxia  (ISO)
cellular response to insulin stimulus  (IEP)
cellular response to interferon-alpha  (ISO)
cellular response to interleukin-1  (IEP)
cellular response to lectin  (IEP)
cellular response to phorbol 13-acetate 12-myristate  (IEP)
cellular response to platelet-derived growth factor stimulus  (IEP)
cellular response to prolactin  (IEP)
cellular response to putrescine  (IEP)
cellular response to retinoic acid  (IEP)
cellular response to testosterone stimulus  (IEP)
cellular response to type II interferon  (IEP)
cellular response to UV  (ISO)
cellular response to xenobiotic stimulus  (IEP,ISO)
chromatin remodeling  (ISO,ISS)
chromosome organization  (ISO,ISS)
detection of mechanical stimulus involved in sensory perception of sound  (ISO)
DNA damage response  (ISO,ISS)
DNA-templated transcription  (IDA)
DNA-templated transcription initiation  (IDA)
ERK1 and ERK2 cascade  (ISO)
G0 to G1 transition  (IEP)
G1/S transition of mitotic cell cycle  (ISO,ISS)
glucose metabolic process  (IMP)
hypothalamus development  (IEP)
in utero embryonic development  (IEP)
inner mitochondrial membrane organization  (IMP)
intracellular iron ion homeostasis  (ISO,ISS)
intrinsic apoptotic signaling pathway in response to DNA damage  (ISO)
lactic acid secretion  (IMP)
liver regeneration  (IEP)
MAPK cascade  (ISO,ISS)
middle ear morphogenesis  (ISO)
myoblast proliferation  (IEP)
myotube differentiation  (ISO)
negative regulation of apoptotic process  (ISO)
negative regulation of cell division  (ISO,ISS)
negative regulation of D-glucose import  (IMP)
negative regulation of epithelial cell apoptotic process  (IMP)
negative regulation of fibroblast proliferation  (ISO)
negative regulation of gene expression  (IMP)
negative regulation of gene expression via chromosomal CpG island methylation  (ISO)
negative regulation of monocyte differentiation  (ISO,ISS)
negative regulation of stress-activated MAPK cascade  (ISO)
negative regulation of transcription by RNA polymerase II  (IMP,ISO)
negative regulation of transcription initiation by RNA polymerase II  (ISO)
NK T cell proliferation  (ISO)
ovarian follicle development  (IEP)
pigmentation  (ISO)
positive regulation of acinar cell proliferation  (ISO)
positive regulation of apoptotic signaling pathway  (ISO)
positive regulation of ATP biosynthetic process  (IMP)
positive regulation of B cell apoptotic process  (ISO)
positive regulation of catalytic activity  (ISO)
positive regulation of cell cycle  (IMP)
positive regulation of cell population proliferation  (IBA,IGI,ISO)
positive regulation of cellular respiration  (IMP)
positive regulation of DNA binding  (IMP)
positive regulation of DNA-templated transcription  (IDA,ISO,ISS)
positive regulation of epithelial cell proliferation  (ISO,ISS)
positive regulation of fibroblast proliferation  (IMP,ISO,ISS)
positive regulation of gene expression  (ISO)
positive regulation of glial cell proliferation  (IMP)
positive regulation of glycolytic process  (IMP)
positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator  (ISO)
positive regulation of mesenchymal cell proliferation  (ISO,ISS)
positive regulation of metanephric cap mesenchymal cell proliferation  (ISO,ISS)
positive regulation of miRNA transcription  (ISO)
positive regulation of mitochondrial membrane potential  (IMP)
positive regulation of oxidative phosphorylation  (IMP)
positive regulation of smooth muscle cell migration  (IMP)
positive regulation of smooth muscle cell proliferation  (IMP)
positive regulation of telomere maintenance  (ISO)
positive regulation of transcription by RNA polymerase II  (IMP,ISO)
positive regulation of transcription initiation by RNA polymerase II  (ISO)
proteasome-mediated ubiquitin-dependent protein catabolic process  (ISO)
protein processing  (ISO)
protein-DNA complex disassembly  (ISO)
pyruvate transport  (IMP)
re-entry into mitotic cell cycle  (IMP)
regulation of apoptotic process  (ISO)
regulation of cell cycle process  (ISO)
regulation of DNA-templated transcription  (IDA,IEA,IMP,ISO,TAS)
regulation of gene expression  (ISO)
regulation of mitotic cell cycle  (IMP)
regulation of oxidative phosphorylation  (IMP)
regulation of somatic stem cell population maintenance  (ISO,ISS)
regulation of telomere maintenance  (ISO,ISS)
regulation of transcription by RNA polymerase II  (IBA)
response to alkaloid  (ISO)
response to estradiol  (IEP)
response to ethanol  (IEP)
response to human chorionic gonadotropin  (IEP)
response to radiation  (ISO)
response to xenobiotic stimulus  (ISO)
rRNA metabolic process  (ISO,ISS)
skeletal muscle cell differentiation  (ISO)
skeletal system morphogenesis  (ISO)
symbiont-mediated transformation of host cell  (IMP)
transcription by RNA polymerase II  (IDA,ISO)
Wnt signaling pathway  (ISO)

Cellular Component

Phenotype Annotations     Click to see Annotation Detail View
References

References - curated
# Reference Title Reference Citation
1. LSD1-mediated demethylation of histone H3 lysine 4 triggers Myc-induced transcription. Amente S, etal., Oncogene. 2010 Jun 24;29(25):3691-702. doi: 10.1038/onc.2010.120. Epub 2010 Apr 26.
2. Evaluation of the potential toxicity of dibromoacetonitrile-induced apoptosis and tumor-initiating activity in rat liver. Assaf N, etal., Food Chem Toxicol. 2011 Dec;49(12):3055-62. doi: 10.1016/j.fct.2011.09.030. Epub 2011 Oct 1.
3. Oncosecretomics coupled to bioenergetics identifies alpha-amino adipic acid, isoleucine and GABA as potential biomarkers of cancer: Differential expression of c-Myc, Oct1 and KLF4 coordinates metabolic changes. Bellance N, etal., Biochim Biophys Acta. 2012 Nov;1817(11):2060-71. doi: 10.1016/j.bbabio.2012.07.004. Epub 2012 Jul 25.
4. Down-regulation of the c-myc proto-oncogene in inhibition of vascular smooth-muscle cell proliferation: a signal for growth arrest? Bennett MR, etal., Biochem J. 1994 Sep 15;302 ( Pt 3):701-8.
5. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. Bennett MR, etal., J Clin Invest. 1994 Feb;93(2):820-8.
6. Point mutations in the c-Myc transactivation domain are common in Burkitt's lymphoma and mouse plasmacytomas. Bhatia K, etal., Nat Genet. 1993 Sep;5(1):56-61.
7. Inhibitory effects of antisense oligodeoxynucleotides targeting c-myc mRNA on smooth muscle cell proliferation and migration. Biro S, etal., Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):654-8.
8. Accumulation of nonphosphorylated beta-catenin and c-myc in primary and uremic secondary hyperparathyroid tumors. Bjorklund P, etal., J Clin Endocrinol Metab. 2007 Jan;92(1):338-44. Epub 2006 Oct 17.
9. Antiproliferative effect of c-myc antisense phosphorothioate oligodeoxynucleotides in malignant glioma cells. Broaddus WC, etal., Neurosurgery. 1997 Oct;41(4):908-15.
10. Polycystic kidneys caused by sustained expression of Cux1 isoform p75. Cadieux C, etal., J Biol Chem. 2008 May 16;283(20):13817-24. doi: 10.1074/jbc.M709332200. Epub 2008 Mar 20.
11. Synergistic effect of malathion and estrogen on mammary gland carcinogenesis. Calaf GM and Echiburu-Chau C, Oncol Rep. 2012 Aug;28(2):640-6. doi: 10.3892/or.2012.1817. Epub 2012 May 17.
12. A Comprehensive Analysis of Cytokine-induced and Nuclear Factor-kappa B-dependent Genes in Primary Rat Pancreatic beta -Cells. Cardozo AK, etal., J Biol Chem 2001 Dec 28;276(52):48879-86.
13. Cross-species genome wide expression analysis during pluripotent cell determination in mouse and rat preimplantation embryos. Casanova EA, etal., PLoS One. 2012;7(10):e47107. doi: 10.1371/journal.pone.0047107. Epub 2012 Oct 15.
14. A role for p38 mitogen-activated protein kinase and c-myc in endothelin-dependent rat aortic smooth muscle cell proliferation. Chen S, etal., Hypertension. 2006 Feb;47(2):252-8. Epub 2005 Dec 19.
15. Mithramycin inhibits myointimal proliferation after balloon injury of the rat carotid artery in vivo. Chen SJ, etal., Circulation. 1994 Nov;90(5):2468-73.
16. beta-Catenin and K-RAS synergize to form primitive renal epithelial tumors with features of epithelial Wilms' tumors. Clark PE, etal., Am J Pathol. 2011 Dec;179(6):3045-55. doi: 10.1016/j.ajpath.2011.08.006. Epub 2011 Oct 8.
17. c-Myc is required for the glucose-mediated induction of metabolic enzyme genes. Collier JJ, etal., J Biol Chem. 2003 Feb 21;278(8):6588-95. Epub 2002 Dec 11.
18. Increased expression of the N-myc gene during normal and neoplastic rat liver growth. Corral M, etal., Exp Cell Res. 1988 Jan;174(1):107-15.
19. Elevated c-myc protooncogene expression in autosomal recessive polycystic kidney disease. Cowley BD Jr, etal., Proc Natl Acad Sci U S A. 1987 Dec;84(23):8394-8.
20. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cuny M, etal., Cancer Res. 2000 Feb 15;60(4):1077-83.
21. Identification of the couple GSK3alpha/c-Myc as a new regulator of hexokinase II in benzopyrene-induced apoptosis. Dendele B, etal., Toxicol In Vitro. 2012 Feb;26(1):94-101. doi: 10.1016/j.tiv.2011.11.001. Epub 2011 Nov 12.
22. WNT10A/ß-catenin pathway in tumorigenesis of papillary thyroid carcinoma. Dong T, etal., Oncol Rep. 2017 Aug;38(2):1287-1294. doi: 10.3892/or.2017.5777. Epub 2017 Jul 3.
23. Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Ellwood-Yen K, etal., Cancer Cell. 2003 Sep;4(3):223-38.
24. Heterogeneous pattern of chromosomal breakpoints involving the MYC locus in multiple myeloma. Fabris S, etal., Genes Chromosomes Cancer. 2003 Jul;37(3):261-9.
25. Differential pathotropism of non-immortalized and immortalized human neural stem cell lines in a focal demyelination model. Ferrari D, etal., Cell Mol Life Sci. 2012 Apr;69(7):1193-210. doi: 10.1007/s00018-011-0873-5. Epub 2011 Nov 11.
26. Combined Stimulation with the Tumor Necrosis Factor alpha and the Epidermal Growth Factor Promotes the Proliferation of Hepatocytes in Rat Liver Cultured Slices. Finot F, etal., Int J Hepatol. 2012;2012:785786. doi: 10.1155/2012/785786. Epub 2012 Oct 16.
27. MYC recruits the TIP60 histone acetyltransferase complex to chromatin. Frank SR, etal., EMBO Rep 2003 Jun;4(6):575-80.
28. An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis. Frau M, etal., Cell Oncol (Dordr). 2012 Jun;35(3):163-73. doi: 10.1007/s13402-011-0067-z. Epub 2012 Mar 21.
29. Malignant transformation of an epithelial cell by v-Src via tv-a-mediated retroviral infection: a new cell model for studying carcinogenesis. Fu SL, etal., Biochem Biophys Res Commun. 2005 Dec 16;338(2):830-8. Epub 2005 Oct 21.
30. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Furge KA, etal., Cancer Res. 2007 Apr 1;67(7):3171-6.
31. Rhabdoid tumor: gene expression clues to pathogenesis and potential therapeutic targets. Gadd S, etal., Lab Invest. 2010 May;90(5):724-38. doi: 10.1038/labinvest.2010.66. Epub 2010 Mar 8.
32. Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium. Gaudet P, etal., Brief Bioinform. 2011 Sep;12(5):449-62. doi: 10.1093/bib/bbr042. Epub 2011 Aug 27.
33. Polysaccharides from Capsosiphon fulvescens stimulate the growth of IEC-6 Cells by activating the MAPK signaling pathway. Go H, etal., Mar Biotechnol (NY). 2011 Jun;13(3):433-40. doi: 10.1007/s10126-010-9314-y. Epub 2010 Aug 10.
34. Rat ISS GO annotations from GOA human gene data--August 2006 GOA data from the GO Consortium
35. Direct activation of RNA polymerase III transcription by c-Myc. Gomez-Roman N, etal., Nature 2003 Jan 16;421(6920):290-4.
36. Mitochondrial structure, function and dynamics are temporally controlled by c-Myc. Graves JA, etal., PLoS One. 2012;7(5):e37699. doi: 10.1371/journal.pone.0037699. Epub 2012 May 21.
37. Acinar-to-ductal metaplasia accompanies c-myc-induced exocrine pancreatic cancer progression in transgenic rodents. Grippo PJ and Sandgren EP, Int J Cancer. 2012 Sep 1;131(5):1243-8. doi: 10.1002/ijc.27322. Epub 2012 Jan 11.
38. 1,25-dihydroxyvitamin D3 treatment shrinks uterine leiomyoma tumors in the Eker rat model. Halder SK, etal., Biol Reprod. 2012 Apr 19;86(4):116. Print 2012 Apr.
39. tPA is a potent mitogen for renal interstitial fibroblasts: role of beta1 integrin/focal adhesion kinase signaling. Hao S, etal., Am J Pathol. 2010 Sep;177(3):1164-75. doi: 10.2353/ajpath.2010.091269. Epub 2010 Jul 16.
40. Characterization of rat c-myc and adjacent regions. Hayashi K, etal., Nucleic Acids Res 1987 Aug 25;15(16):6419-36.
41. Wnt/beta-catenin signaling promotes renal interstitial fibrosis. He W, etal., J Am Soc Nephrol. 2009 Apr;20(4):765-76. doi: 10.1681/ASN.2008060566. Epub 2009 Mar 18.
42. The let-7a microRNA protects from growth of lung carcinoma by suppression of k-Ras and c-Myc in nude mice. He XY, etal., J Cancer Res Clin Oncol. 2010 Jul;136(7):1023-8. doi: 10.1007/s00432-009-0747-5. Epub 2009 Dec 22.
43. Hepatitis C virus-induced activation of β-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events. Higgs MR, etal., Oncogene. 2013 Sep 26;32(39):4683-93. doi: 10.1038/onc.2012.484. Epub 2012 Oct 29.
44. Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model. Hosseini A, etal., J Ocul Pharmacol Ther. 2012 Apr;28(2):194-201. doi: 10.1089/jop.2011.0135. Epub 2011 Dec 7.
45. Down-regulation of β-catenin and the associated migration ability by Taiwanin C in arecoline and 4-NQO-induced oral cancer cells via GSK-3β activation. Hsieh CH, etal., Mol Carcinog. 2017 Mar;56(3):1055-1067. doi: 10.1002/mc.22570. Epub 2016 Oct 4.
46. MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. Iwata T, etal., PLoS One. 2010 Feb 25;5(2):e9427. doi: 10.1371/journal.pone.0009427.
47. c-Myc and ChREBP regulate glucose-mediated expression of the L-type pyruvate kinase gene in INS-1-derived 832/13 cells. Jason Collier J, etal., Am J Physiol Endocrinol Metab. 2007 Jul;293(1):E48-56. Epub 2007 Mar 6.
48. Resveratrol improves cardiac contractility following trauma-hemorrhage by modulating Sirt1. Jian B, etal., Mol Med. 2012 Mar 27;18:209-14. doi: 10.2119/molmed.2011.00365.
49. Gain of MYC underlies recurrent trisomy of the MYC chromosome in acute promyelocytic leukemia. Jones L, etal., J Exp Med. 2010 Nov 22;207(12):2581-94. doi: 10.1084/jem.20091071. Epub 2010 Nov 8.
50. AP4 encodes a c-MYC-inducible repressor of p21. Jung P, etal., Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15046-51. doi: 10.1073/pnas.0801773105. Epub 2008 Sep 25.
51. Induction of c-Myc expression suppresses insulin gene transcription by inhibiting NeuroD/BETA2-mediated transcriptional activation. Kaneto H, etal., J Biol Chem 2002 Apr 12;277(15):12998-3006.
52. Rat alpha-fetoprotein heterogeneity. Comparative chemical study of the two electrophoretic variants and their Ricinus lectin-binding properties. Kerckaert JP, etal., Biochim Biophys Acta 1977 Aug 23;493(2):293-303.
53. Identification of gene expression signature modulated by nicotinamide in a mouse bladder cancer model. Kim SK, etal., PLoS One. 2011;6(10):e26131. doi: 10.1371/journal.pone.0026131. Epub 2011 Oct 10.
54. c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway. Klefstrom J, etal., J Biol Chem 2002 Nov 8;277(45):43224-32.
55. Ellagic acid modulates antioxidant status, ornithine decarboxylase expression, and aberrant crypt foci progression in 1,2-dimethylhydrazine-instigated colon preneoplastic lesions in rats. Kumar KN, etal., J Agric Food Chem. 2012 Apr 11;60(14):3665-72. doi: 10.1021/jf204128z. Epub 2012 Apr 3.
56. Deregulated expression of a novel component of TFTC/STAGA histone acetyltransferase complexes, rat SGF29, in hepatocellular carcinoma: possible implication for the oncogenic potential of c-Myc. Kurabe N, etal., Oncogene. 2007 Aug 16;26(38):5626-34. Epub 2007 Mar 5.
57. Genomewide expression profiles of rat model renal isografts from brain dead donors. Kusaka M, etal., Transplantation. 2007 Jan 15;83(1):62-70.
58. Prepubertal onset of diabetes prevents expression of renal cortical connective tissue growth factor. Langer WJ, etal., Pediatr Nephrol. 2008 Feb;23(2):275-83. Epub 2007 Nov 21.
59. Differential expression of protooncogenes related to transformation and cancer progression in rat myoblasts. Leibovitch SA, etal., Cancer Res. 1986 Aug;46(8):4097-103.
60. Cannabis exposure associated with weight reduction and beta-cell protection in an obese rat model. Levendal RA, etal., Phytomedicine. 2012 May 15;19(7):575-82. doi: 10.1016/j.phymed.2012.02.001. Epub 2012 Mar 14.
61. Chinese Herbal Formulas Miao-Yi-Ai-Tang Inhibits the Proliferation and Migration of Lung Cancer Cells through Targeting β-Catenin/AXIN and Presents Synergistic Effect with Cisplatin Suppressing Lung Cancer. Li B, etal., Biomed Res Int. 2020 Jan 16;2020:2761850. doi: 10.1155/2020/2761850. eCollection 2020.
62. Angiotensin II Reduces Cardiac AdipoR1 Expression through AT1 Receptor/ROS/ERK1/2/c-Myc Pathway. Li L, etal., PLoS One. 2013;8(1):e49915. doi: 10.1371/journal.pone.0049915. Epub 2013 Jan 22.
63. Astilbin inhibits proliferation of rat aortic smooth muscle cells induced by angiotensin II and down-regulates expression of protooncogene. Li P, etal., J Huazhong Univ Sci Technolog Med Sci. 2012 Apr;32(2):181-5. doi: 10.1007/s11596-012-0032-8. Epub 2012 Apr 20.
64. Inhibitory effect of calcitonin gene-related peptide on hypoxia-induced rat pulmonary artery smooth muscle cells proliferation: role of ERK1/2 and p27. Li XW, etal., Eur J Pharmacol. 2012 Mar 15;679(1-3):117-26. doi: 10.1016/j.ejphar.2012.01.015. Epub 2012 Jan 28.
65. Testosterone regulation of proto-oncogene c-myc expression in primary Sertoli cell cultures from prepubertal rats. Lim K, etal., J Androl. 1994 Nov-Dec;15(6):543-50.
66. Targeted overexpression of an activated N-ras gene results in B-cell and plasma cell lymphoproliferation and cooperates with c-myc to induce fatal B-cell neoplasia. Linden MA, etal., Exp Hematol. 2012 Mar;40(3):216-27. doi: 10.1016/j.exphem.2011.11.006. Epub 2011 Nov 23.
67. Activation of Wnt3a signaling stimulates intestinal epithelial repair by promoting c-Myc-regulated gene expression. Liu L, etal., Am J Physiol Cell Physiol. 2012 Jan 1;302(1):C277-85. doi: 10.1152/ajpcell.00341.2011. Epub 2011 Oct 5.
68. Comprehensive analysis of clinical significance of stem-cell related factors in renal cell cancer. Liu Y, etal., World J Surg Oncol. 2011 Oct 7;9:121. doi: 10.1186/1477-7819-9-121.
69. Chronic oxidative stress causes amplification and overexpression of ptprz1 protein tyrosine phosphatase to activate beta-catenin pathway. Liu YT, etal., Am J Pathol. 2007 Dec;171(6):1978-88. Epub 2007 Nov 30.
70. Intratracheal administration of p38alpha short-hairpin RNA plasmid ameliorates lung ischemia-reperfusion injury in rats. Lv X, etal., J Heart Lung Transplant. 2012 Jun;31(6):655-62. doi: 10.1016/j.healun.2012.03.001. Epub 2012 Apr 13.
71. Preventive and protective effects of silymarin on doxorubicin-induced testicular damages correlate with changes in c-myc gene expression. Malekinejad H, etal., Phytomedicine. 2012 Sep 15;19(12):1077-84. doi: 10.1016/j.phymed.2012.06.011. Epub 2012 Jul 20.
72. Rat ISS GO annotations from MGI mouse gene data--August 2006 MGD data from the GO Consortium
73. MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. Mollaoglu G, etal., Cancer Cell. 2017 Feb 13;31(2):270-285. doi: 10.1016/j.ccell.2016.12.005. Epub 2017 Jan 12.
74. Modulation of c-myc gene expression by extracellular stimuli in rat hepatoma cells. Morimura S, etal., Jpn J Exp Med. 1990 Apr;60(2):51-6.
75. The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. Morrish F, etal., Cell Cycle. 2008 Apr 15;7(8):1054-66. Epub 2008 Feb 8.
76. c-MYC apoptotic function is mediated by NRF-1 target genes. Morrish F, etal., Genes Dev 2003 Jan 15;17(2):240-55.
77. Targeted massively parallel sequencing of angiosarcomas reveals frequent activation of the mitogen activated protein kinase pathway. Murali R, etal., Oncotarget. 2015 Nov 3;6(34):36041-52. doi: 10.18632/oncotarget.5936.
78. Transmural pressure loading enhances gastric mucosal cell proliferation. Nakamizo H, etal., Dig Dis Sci. 2012 Oct;57(10):2545-54. Epub 2012 May 30.
79. Electronic Transfer of LocusLink and RefSeq Data NCBI rat LocusLink and RefSeq merged data July 26, 2002
80. Transgenic overexpression of Anks6(p.R823W) causes polycystic kidney disease in rats. Neudecker S, etal., Am J Pathol. 2010 Dec;177(6):3000-9. doi: 10.2353/ajpath.2010.100569.
81. Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. Nevzorova YA, etal., Biochim Biophys Acta. 2013 Oct;1832(10):1765-75. doi: 10.1016/j.bbadis.2013.06.001. Epub 2013 Jun 12.
82. Enhanced expression of c-myc in hepatocytes promotes initiation and progression of alcoholic liver disease. Nevzorova YA, etal., J Hepatol. 2016 Mar;64(3):628-40. doi: 10.1016/j.jhep.2015.11.005. Epub 2015 Nov 11.
83. The Proto-oncogene c-myc Acts through the Cyclin-dependent Kinase (Cdk) Inhibitor p27Kip1 to Facilitate the Activation of Cdk4/6 and Early G1 Phase Progression. Obaya AJ, etal., J Biol Chem 2002 Aug 23;277(34):31263-9.
84. Modulation of c-myc and c-fos gene expression in regenerating rat liver by 2-mercaptopropionylglycine. Ohri S, etal., Cell Biol Int 2002;26(2):187-92.
85. Amelioration of cisplatin-induced nephrotoxicity in peroxiredoxin I-deficient mice. Okada K, etal., Cancer Chemother Pharmacol. 2013 Feb;71(2):503-9. doi: 10.1007/s00280-012-2046-0. Epub 2012 Dec 11.
86. OMIM Disease Annotation Pipeline OMIM Disease Annotation Pipeline
87. Alcohol increases c-myc mRNA and protein in skeletal and cardiac muscle. Paice AG, etal., Metabolism. 2002 Oct;51(10):1285-90.
88. MicroRNA profiling of carcinogen-induced rat colon tumors and the influence of dietary spinach. Parasramka MA, etal., Mol Nutr Food Res. 2012 Aug;56(8):1259-69. doi: 10.1002/mnfr.201200117. Epub 2012 May 29.
89. The expression of c-myc during follicular growth and luteal formation in the rat ovary in vivo. Piontkewitz Y, etal., J Endocrinol. 1997 Mar;152(3):395-406.
90. KEGG Annotation Import Pipeline Pipeline to import KEGG annotations from KEGG into RGD
91. PID Annotation Import Pipeline Pipeline to import Pathway Interaction Database annotations from NCI into RGD
92. GOA pipeline RGD automated data pipeline
93. ClinVar Automated Import and Annotation Pipeline RGD automated import pipeline for ClinVar variants, variant-to-disease annotations and gene-to-disease annotations
94. Data Import for Chemical-Gene Interactions RGD automated import pipeline for gene-chemical interactions
95. Combined serum and tissue proteomic study applied to a c-Myc transgenic mouse model of hepatocellular carcinoma identified novel disease regulated proteins suitable for diagnosis and therapeutic intervention strategies. Ritorto MS and Borlak J, J Proteome Res. 2011 Jul 1;10(7):3012-30. Epub 2011 Jun 6.
96. Mammary gland morphology and gene expression differ in female rats treated with 17beta-estradiol or fed soy protein isolate. Ronis MJ, etal., Endocrinology. 2012 Dec;153(12):6021-32. doi: 10.1210/en.2012-1591. Epub 2012 Oct 1.
97. Multiple independent genetic variants in the 8q24 region are associated with prostate cancer risk. Salinas CA, etal., Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1203-13. doi: 10.1158/1055-9965.EPI-07-2811.
98. Coordinated regulation of c-Myc and Max in rat liver development. Sanders JA and Gruppuso PA, Am J Physiol Gastrointest Liver Physiol. 2006 Jan;290(1):G145-55. Epub 2005 Sep 8.
99. Nucleolar localization of hepatic c-Myc: a potential mechanism for c-Myc regulation. Sanders JA and Gruppuso PA, Biochim Biophys Acta. 2005 Mar 22;1743(1-2):141-50.
100. Changes in Hypothalamic Expression of the Lin28/let-7 System and Related MicroRNAs During Postnatal Maturation and After Experimental Manipulations of Puberty. Sangiao-Alvarellos S, etal., Endocrinology. 2013 Feb;154(2):942-55. doi: 10.1210/en.2012-2006. Epub 2013 Jan 4.
101. Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas. Schultz L, etal., Am J Surg Pathol. 2011 Oct;35(10):1549-56. doi: 10.1097/PAS.0b013e31822895e5.
102. Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Schultz L, etal., Cancer. 2010 Dec 1;116(23):5517-26. doi: 10.1002/cncr.25502. Epub 2010 Oct 11.
103. Distinct SNP combinations confer susceptibility to urinary bladder cancer in smokers and non-smokers. Schwender H, etal., PLoS One. 2012;7(12):e51880. doi: 10.1371/journal.pone.0051880. Epub 2012 Dec 20.
104. Epigallocatechin gallate, the major component of polyphenols in green tea, inhibits telomere attrition mediated cardiomyocyte apoptosis in cardiac hypertrophy. Sheng R, etal., Int J Cardiol. 2013 Jan 20;162(3):199-209. doi: 10.1016/j.ijcard.2011.07.083. Epub 2011 Oct 15.
105. Antioxidant N-acetyl-L-cysteine (NAC) supplementation reduces reactive oxygen species (ROS)-mediated hepatocellular tumor promotion of indole-3-carbinol (I3C) in rats. Shimamoto K, etal., J Toxicol Sci. 2011;36(6):775-86.
106. Effect of glutathione depletion and metallothionein gene expression on arsenic-induced cytotoxicity and c-myc expression in vitro. Shimizu M, etal., Toxicol Sci. 1998 Oct;45(2):204-11.
107. BRCA1 affects global DNA methylation through regulation of DNMT1. Shukla V, etal., Cell Res. 2010 Nov;20(11):1201-15. doi: 10.1038/cr.2010.128. Epub 2010 Sep 7.
108. c-myc and skp2 coordinate p27 degradation, vascular smooth muscle proliferation, and neointima formation induced by the parathyroid hormone-related protein. Sicari BM, etal., Endocrinology. 2012 Feb;153(2):861-72. doi: 10.1210/en.2011-1590. Epub 2011 Dec 30.
109. The PTEN regulator DJ-1 is associated with hTERT expression in clear cell renal cell carcinoma. Sitaram RT, etal., Int J Cancer. 2009 Aug 15;125(4):783-90. doi: 10.1002/ijc.24335.
110. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational identification of gene expression pathways and integrated regulatory networks. Song X, etal., Hum Mol Genet. 2009 Jul 1;18(13):2328-43. doi: 10.1093/hmg/ddp165. Epub 2009 Apr 3.
111. Effects of all-trans retinoic acid as a potential chemopreventive agent on the formation of azoxymethane-induced aberrant crypt foci: differential expression of c-myc and c-fos MRNA and protein. Stopera SA and Bird RP, Int J Cancer. 1993 Mar 12;53(5):798-803.
112. Activation of cell cycle regulatory proteins in the apoptosis of terminally differentiated oligodendrocytes. Strazza M, etal., Neurochem Res. 2004 May;29(5):923-31.
113. Thyroglobulin (Tg) activates MAPK pathway to induce thyroid cell growth in the absence of TSH, insulin and serum. Sue M, etal., Biochem Biophys Res Commun. 2012 Apr 13;420(3):611-5. doi: 10.1016/j.bbrc.2012.03.046. Epub 2012 Mar 16.
114. Effects of Ganoderma lucidum polysaccharides on IEC-6 cell proliferation, migration and morphology of differentiation benefiting intestinal epithelium healing in vitro. Sun LX, etal., J Pharm Pharmacol. 2011 Dec;63(12):1595-603. doi: 10.1111/j.2042-7158.2011.01367.x. Epub 2011 Oct 13.
115. Activation of the proto-oncogene c-myc and c-fos by c-ras: involvement of polyamines. Tabib A and Bachrach U, Biochem Biophys Res Commun. 1994 Jul 29;202(2):720-7.
116. Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor. Tarasenko N, etal., PLoS One. 2012;7(2):e31393. doi: 10.1371/journal.pone.0031393. Epub 2012 Feb 23.
117. Mechanistic study on liver tumor promoting effects of flutamide in rats. Tawfeeq MM, etal., Arch Toxicol. 2012 Mar;86(3):497-507. doi: 10.1007/s00204-011-0776-0. Epub 2011 Nov 11.
118. Tentative Sequence Identification Numbers Tentative Sequence Data IDs. TIGR Gene Index, Rat Data
119. Overexpression of PKD1 causes polycystic kidney disease. Thivierge C, etal., Mol Cell Biol. 2006 Feb;26(4):1538-48.
120. Downregulation of cytochromes P450 in growth-stimulated rat hepatocytes: role of c-Myc induction and impaired C/EBP binding to DNA. Tinel M, etal., J Hepatol. 2003 Aug;39(2):171-8.
121. Genomic characterization of human and rat prolactinomas. Tong Y, etal., Endocrinology. 2012 Aug;153(8):3679-91. doi: 10.1210/en.2012-1056. Epub 2012 May 25.
122. CEBPD suppresses prolactin expression and prolactinoma cell proliferation. Tong Y, etal., Mol Endocrinol. 2011 Nov;25(11):1880-91. doi: 10.1210/me.2011-1075. Epub 2011 Oct 6.
123. Differential expression of elongation factor-2, alpha4 phosphoprotein and Cdc5-like protein in prolactin-dependent/independent rat lymphoid cells. Too CK Mol Cell Endocrinol 1997 Aug 8;131(2):221-32.
124. Polycystic kidney disease in SBM transgenic mice: role of c-myc in disease induction and progression. Trudel M, etal., Am J Pathol. 1998 Jan;152(1):219-29.
125. Growth hormone directly and indirectly stimulates articular chondrocyte cell growth. Tsukazaki T, etal., Osteoarthritis Cartilage. 1994 Dec;2(4):259-67.
126. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Wang J, etal., Oncogene. 2010 Apr 29;29(17):2477-87. doi: 10.1038/onc.2010.10. Epub 2010 Feb 8.
127. Pro-inflammatory cytokine interleukin-1beta promotes the development of intestinal stem cells. Wang L, etal., Inflamm Res. 2012 Oct;61(10):1085-92. doi: 10.1007/s00011-012-0501-3. Epub 2012 Jun 16.
128. Inhibitory effects of lupeal acetate of Cortex periplocae on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Wang L, etal., Oncol Lett. 2012 Aug;4(2):231-236. Epub 2012 May 16.
129. Function of BRD4 in the pathogenesis of high glucose‑induced cardiac hypertrophy. Wang Q, etal., Mol Med Rep. 2019 Jan;19(1):499-507. doi: 10.3892/mmr.2018.9681. Epub 2018 Nov 21.
130. Inhibitory effects of emodin on the proliferation of cultured rat vascular smooth muscle cell-induced by angiotensin II. Wang S, etal., Phytother Res. 2008 Feb;22(2):247-51.
131. Expression and subcellular localization of the Myc superfamily proteins: c-Myc, Max, Mad1 and Mxi1 in the epiphyseal plate cartilage chondrocytes of growing rats. Wang Y, etal., Cell Mol Biol (Noisy-le-grand). 1997 Mar;43(2):175-88.
132. New prognostic markers revealed by evaluation of genes correlated with clinical parameters in Wilms tumors. Wittmann S, etal., Genes Chromosomes Cancer. 2008 May;47(5):386-95. doi: 10.1002/gcc.20544.
133. Coordinated regulation of iron-controlling genes, H-ferritin and IRP2, by c-MYC. Wu KJ, etal., Science. 1999 Jan 29;283(5402):676-9.
134. The effect of 2,3,4',5-tetrahydroxystilbene-2-0-beta-D glucoside on neointima formation in a rat artery balloon injury model and its possible mechanisms. Xu XL, etal., Eur J Pharmacol. 2013 Jan 5;698(1-3):370-8. doi: 10.1016/j.ejphar.2012.11.019. Epub 2012 Nov 21.
135. Mechanisms of prostate atrophy after LHRH antagonist cetrorelix injection: an experimental study in a rat model of benign prostatic hyperplasia. Yang D, etal., J Huazhong Univ Sci Technolog Med Sci. 2012 Jun;32(3):389-95. doi: 10.1007/s11596-012-0067-x. Epub 2012 Jun 9.
136. Knockdown of lncRNA H19 alleviates ox-LDL-induced HCAECs inflammation and injury by mediating miR-20a-5p/HDAC4 axis. Yang Y, etal., Inflamm Res. 2022 Sep;71(9):1109-1121. doi: 10.1007/s00011-022-01604-z. Epub 2022 Jul 19.
137. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma. Yano T, etal., Oncogene. 1993 Oct;8(10):2741-8.
138. p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia. Yetil A, etal., Oncotarget. 2015 Feb 28;6(6):3563-77.
139. Identification of Myc-mediated death response pathways by microarray analysis. Yu Q, etal., J Biol Chem 2002 Apr 12;277(15):13059-66.
140. Ginsenoside Rb(1) inhibits the carotid neointimal hyperplasia induced by balloon injury in rats via suppressing the phenotype modulation of vascular smooth muscle cells. Zhang S, etal., Eur J Pharmacol. 2012 Jun 15;685(1-3):126-32. doi: 10.1016/j.ejphar.2012.04.032. Epub 2012 Apr 21.
141. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Zhang W, etal., Proc Natl Acad Sci U S A. 2010 Nov 2;107(44):18956-60. doi: 10.1073/pnas.1013420107. Epub 2010 Oct 18.
142. Prostatic neoplasia in transgenic mice with prostate-directed overexpression of the c-myc oncoprotein. Zhang X, etal., Prostate. 2000 Jun 1;43(4):278-85.
143. Von Willebrand Factor permeates small vessels in CADASIL and inhibits smooth muscle gene expression. Zhang X, etal., Transl Stroke Res. 2012 Mar 1;3(1):138-145. Epub 2011 Oct 20.
144. Effects of pulsed electromagnetic fields on bone mass and Wnt/beta-catenin signaling pathway in ovariectomized rats. Zhou J, etal., Arch Med Res. 2012 May;43(4):274-82. doi: 10.1016/j.arcmed.2012.06.002. Epub 2012 Jun 13.
145. Synergistic signaling of KRAS and thyroid hormone receptor ß mutants promotes undifferentiated thyroid cancer through MYC up-regulation. Zhu X, etal., Neoplasia. 2014 Sep;16(9):757-69. doi: 10.1016/j.neo.2014.08.003.
Additional References at PubMed
PMID:3284178   PMID:8521822   PMID:9637678   PMID:10482234   PMID:10723141   PMID:10962037   PMID:11438662   PMID:11604501   PMID:11793365   PMID:11872843   PMID:11939505   PMID:12138190  
PMID:12167710   PMID:12196193   PMID:12235125   PMID:12477932   PMID:12631706   PMID:12837246   PMID:12970171   PMID:12970677   PMID:14517295   PMID:14560010   PMID:14651961   PMID:14990581  
PMID:15192039   PMID:15358760   PMID:15371245   PMID:15459207   PMID:15489334   PMID:15509711   PMID:15511642   PMID:15616584   PMID:15674325   PMID:15735755   PMID:15867157   PMID:15922606  
PMID:15989779   PMID:15994933   PMID:16123140   PMID:16352593   PMID:16365299   PMID:16407335   PMID:16724113   PMID:16776654   PMID:16785237   PMID:16788862   PMID:17190142   PMID:17377531  
PMID:17382917   PMID:17523175   PMID:17558397   PMID:17596282   PMID:17631878   PMID:17700062   PMID:17765874   PMID:17873522   PMID:17953200   PMID:17993259   PMID:18045875   PMID:18218323  
PMID:18291362   PMID:18348166   PMID:18386196   PMID:18405607   PMID:18483244   PMID:18544539   PMID:18625840   PMID:18628958   PMID:18779656   PMID:18816594   PMID:18987311   PMID:19017648  
PMID:19041662   PMID:19056892   PMID:19061498   PMID:19160485   PMID:19161241   PMID:19176757   PMID:19179467   PMID:19258038   PMID:19270725   PMID:19289167   PMID:19448666   PMID:19545562  
PMID:19642983   PMID:19786833   PMID:19796622   PMID:19812253   PMID:19966300   PMID:20111719   PMID:20212154   PMID:20382893   PMID:20424134   PMID:21181359   PMID:21187408   PMID:21404708  
PMID:21447833   PMID:21533051   PMID:21623162   PMID:21678465   PMID:21885567   PMID:22147266   PMID:22328504   PMID:22723415   PMID:23277542   PMID:23287475   PMID:23612979   PMID:23828673  
PMID:24001804   PMID:24013231   PMID:24083763   PMID:24311629   PMID:24795346   PMID:25053415   PMID:25056450   PMID:25175461   PMID:25450615   PMID:25775507   PMID:25956029   PMID:26135564  
PMID:26320084   PMID:26691508   PMID:26962537   PMID:27889560   PMID:28616752   PMID:29211809   PMID:30129147   PMID:30243650   PMID:30715622   PMID:30873824   PMID:31005419   PMID:31344482  
PMID:31549850   PMID:31787253   PMID:33086033   PMID:33262248   PMID:35016888   PMID:36591933   PMID:38042369  


Genomics

Comparative Map Data
Myc
(Rattus norvegicus - Norway rat)
Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCr8795,483,105 - 95,488,031 (+)NCBIGRCr8GRCr8GRCr8
GRCr8 Ensembl795,483,105 - 95,488,028 (+)EnsemblGRCr8
mRatBN7.2793,593,705 - 93,598,633 (+)NCBImRatBN7.2mRatBN7.2
mRatBN7.2 Ensembl793,593,705 - 93,598,630 (+)EnsemblmRatBN7.2
UTH_Rnor_SHR_Utx795,416,828 - 95,421,746 (+)NCBIUTH_Rnor_SHR_UtxUTH_Rnor_SHR_Utx
UTH_Rnor_SHRSP_BbbUtx_1.0797,619,124 - 97,624,042 (+)NCBIUTH_Rnor_SHRSP_BbbUtx_1.0UTH_Rnor_SHRSP_BbbUtx_1.0
UTH_Rnor_WKY_Bbb_1.0797,498,652 - 97,503,571 (+)NCBIUTH_Rnor_WKY_Bbb_1.0UTH_Rnor_WKY_Bbb_1.0
Rnor_6.07102,586,313 - 102,591,240 (+)NCBIRnor_6.0Rnor_6.0rn6Rnor6.0
Rnor_6.0 Ensembl7102,586,313 - 102,591,240 (+)Ensemblrn6Rnor6.0
Rnor_5.07103,157,452 - 103,162,379 (+)NCBIRnor_5.0Rnor_5.0rn5
RGSC_v3.4798,953,142 - 98,958,060 (+)NCBIRGSC_v3.4RGSC_v3.4rn4
Celera790,263,903 - 90,268,823 (+)NCBICelera
RGSC_v3.1798,987,371 - 98,992,287 (+)NCBI
Cytogenetic Map7q33NCBI
MYC
(Homo sapiens - human)
Human AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCh388127,735,434 - 127,742,951 (+)NCBIGRCh38GRCh38hg38GRCh38
GRCh38.p14 Ensembl8127,735,434 - 127,742,951 (+)Ensemblhg38GRCh38
GRCh378128,747,680 - 128,755,197 (+)NCBIGRCh37GRCh37hg19GRCh37
Build 368128,817,498 - 128,822,856 (+)NCBIBuild 36Build 36hg18NCBI36
Build 348128,817,685 - 128,822,853NCBI
Celera8124,928,812 - 124,934,177 (+)NCBICelera
Cytogenetic Map8q24.21NCBI
HuRef8124,069,829 - 124,075,195 (+)NCBIHuRef
CHM1_18128,788,551 - 128,793,916 (+)NCBICHM1_1
T2T-CHM13v2.08128,862,888 - 128,870,405 (+)NCBIT2T-CHM13v2.0
Myc
(Mus musculus - house mouse)
Mouse AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
GRCm391561,857,190 - 61,862,210 (+)NCBIGRCm39GRCm39mm39
GRCm39 Ensembl1561,857,240 - 61,862,223 (+)EnsemblGRCm39 EnsemblGRCm39
GRCm381561,985,341 - 61,990,361 (+)NCBIGRCm38GRCm38mm10GRCm38
GRCm38.p6 Ensembl1561,985,391 - 61,990,374 (+)Ensemblmm10GRCm38
MGSCv371561,816,896 - 61,821,916 (+)NCBIMGSCv37MGSCv37mm9NCBIm37
MGSCv361561,815,052 - 61,820,027 (+)NCBIMGSCv36mm8
Celera1563,490,745 - 63,495,748 (+)NCBICelera
Cytogenetic Map15D1NCBI
cM Map1526.19NCBI
Myc
(Chinchilla lanigera - long-tailed chinchilla)
Chinchilla AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChiLan1.0 EnsemblNW_0049554612,714,022 - 2,718,982 (+)Ensembl
ChiLan1.0NW_0049554612,714,022 - 2,718,872 (+)NCBIChiLan1.0ChiLan1.0
MYC
(Pan paniscus - bonobo/pygmy chimpanzee)
Bonobo AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
NHGRI_mPanPan1-v27145,127,238 - 145,132,177 (+)NCBINHGRI_mPanPan1-v2
NHGRI_mPanPan18120,636,992 - 120,641,918 (+)NCBINHGRI_mPanPan1
Mhudiblu_PPA_v08124,387,561 - 124,393,551 (+)NCBIMhudiblu_PPA_v0Mhudiblu_PPA_v0panPan3
PanPan1.18127,130,877 - 127,136,861 (+)NCBIPanPan1.1PanPan1.1panPan2
PanPan1.1 Ensembl8127,131,512 - 127,136,863 (+)EnsemblpanPan2panpan1.1
MYC
(Canis lupus familiaris - dog)
Dog AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
CanFam3.11325,200,772 - 25,205,309 (+)NCBICanFam3.1CanFam3.1canFam3CanFam3.1
CanFam3.1 Ensembl1325,200,577 - 25,205,309 (+)EnsemblcanFam3CanFam3.1
Dog10K_Boxer_Tasha1325,169,176 - 25,173,718 (+)NCBIDog10K_Boxer_TashaDog10K_Boxer_Tasha
ROS_Cfam_1.01325,544,697 - 25,549,239 (+)NCBIROS_Cfam_1.0ROS_Cfam_1.0
ROS_Cfam_1.0 Ensembl1325,539,647 - 25,549,749 (+)EnsemblROS_Cfam_1.0 Ensembl
UMICH_Zoey_3.11325,260,451 - 25,264,991 (+)NCBIUMICH_Zoey_3.1
UNSW_CanFamBas_1.01325,374,618 - 25,379,158 (+)NCBIUNSW_CanFamBas_1.0
UU_Cfam_GSD_1.01325,629,077 - 25,633,621 (+)NCBIUU_Cfam_GSD_1.0UU_Cfam_GSD_1.0
Myc
(Ictidomys tridecemlineatus - thirteen-lined ground squirrel)
Squirrel AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HiC_Itri_2NW_02440530313,054,869 - 13,059,826 (-)NCBIHiC_Itri_2
SpeTri2.0 EnsemblNW_00493647020,480,829 - 20,485,965 (-)EnsemblSpeTri2.0 Ensembl
SpeTri2.0NW_00493647020,480,844 - 20,485,955 (-)NCBISpeTri2.0SpeTri2.0SpeTri2.0
MYC
(Sus scrofa - pig)
Pig AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
Sscrofa11.1 Ensembl412,455,122 - 12,461,078 (-)EnsemblsusScr11Sscrofa11.1
Sscrofa11.1412,455,141 - 12,460,360 (-)NCBISscrofa11.1Sscrofa11.1susScr11Sscrofa11.1
Sscrofa10.2412,778,452 - 12,783,667 (-)NCBISscrofa10.2Sscrofa10.2susScr3
Pig Cytomap4p13NCBI
MYC
(Chlorocebus sabaeus - green monkey)
Green Monkey AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
ChlSab1.18122,282,989 - 122,288,392 (+)NCBIChlSab1.1ChlSab1.1chlSab2
ChlSab1.1 Ensembl8122,282,630 - 122,288,384 (+)EnsemblChlSab1.1 EnsemblchlSab2Vervet-AGM
Vero_WHO_p1.0NW_02366603917,837,088 - 17,843,111 (-)NCBIVero_WHO_p1.0Vero_WHO_p1.0
Myc
(Heterocephalus glaber - naked mole-rat)
Naked Mole-Rat AssemblyChrPosition (strand)SourceGenome Browsers
JBrowseNCBIUCSCEnsembl
HetGla_female_1.0 EnsemblNW_00462473527,780,037 - 27,784,806 (-)EnsemblHetGla_female_1.0 EnsemblhetGla2HetGla_female_1.0 Ensembl
HetGla 1.0NW_00462473527,780,338 - 27,784,714 (-)NCBIHetGla 1.0HetGla 1.0hetGla2

Variants

.
Variants in Myc
15 total Variants
miRNA Target Status (No longer updated)

Confirmed Target Of
miRNA GeneMature miRNAMethod NameResult TypeData TypeSupport TypePMID
Mir18arno-miR-18a-5pMirtarbaseexternal_infoWestern blotFunctional MTI19167416

Predicted Target Of
Summary Value
Count of predictions:262
Count of miRNA genes:153
Interacting mature miRNAs:176
Transcripts:ENSRNOT00000006188
Prediction methods:Microtar, Miranda, Rnahybrid, Targetscan
Result types:miRGate_prediction

The detailed report is available here: Full Report CSV TAB Printer

miRNA Target Status data imported from miRGate (http://mirgate.bioinfo.cnio.es/).
For more information about miRGate, see PMID:25858286 or access the full paper here.


QTLs in Region (GRCr8)
The following QTLs overlap with this region.    Full Report CSV TAB Printer Gviewer
RGD IDSymbolNameLODP ValueTraitSub TraitChrStartStopSpecies
1300179Kidm5Kidney mass QTL 53.51kidney mass (VT:0002707)left kidney wet weight (CMO:0000083)743747012135012528Rat
1331728Bp214Blood pressure QTL 2142.825arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)780221299124373579Rat
2298475Eau6Experimental allergic uveoretinitis QTL 60.0029uvea integrity trait (VT:0010551)experimental autoimmune uveitis score (CMO:0001504)784257275129257275Rat
2317035Aia16Adjuvant induced arthritis QTL 162.71joint integrity trait (VT:0010548)right rear ankle joint diameter (CMO:0002150)759238038104238038Rat
71114Niddm14Non-insulin dependent diabetes mellitus QTL 144.5blood glucose amount (VT:0000188)plasma glucose level (CMO:0000042)784257275129257275Rat
1358361Sradr5Stress Responsive Adrenal Weight QTL 55.55adrenal gland mass (VT:0010420)both adrenal glands wet weight (CMO:0000164)743747012108555253Rat
631687Hcas1Hepatocarcinoma susceptibility QTL 13.90.001liver integrity trait (VT:0010547)liver tumorous lesion volume to total liver volume ratio (CMO:0001082)791412594129807172Rat
1357338Stl17Serum triglyceride level QTL 173.23blood triglyceride amount (VT:0002644)serum triglyceride level (CMO:0000360)769736356112729554Rat
634331Pia17Pristane induced arthritis QTL 174.7joint integrity trait (VT:0010548)arthritic paw count (CMO:0001460)773829340130221005Rat
10450828Scl79Serum cholesterol level QTL 793.50.001blood HDL cholesterol amount (VT:0000184)blood low density lipoprotein cholesterol level (CMO:0000053)789867376101773158Rat
61397Bw17Body weight QTL 176.3body mass (VT:0001259)body weight (CMO:0000012)793595647106839474Rat
1358914Bp266Blood pressure QTL 266arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)783591953134666232Rat
631504Cm27Cardiac mass QTL 273.45heart left ventricle mass (VT:0007031)heart left ventricle wet weight (CMO:0000071)744421311118198041Rat
634322Bw12Body weight QTL 120body mass (VT:0001259)body weight (CMO:0000012)783153392128153392Rat
70173Niddm19Non-insulin dependent diabetes mellitus QTL 194.330.00005blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)764002457135012528Rat
1549899Stresp8Stress response QTL 84.370.0008stress-related behavior trait (VT:0010451)defensive burying duration (CMO:0001961)790482196135012528Rat
1331723Bw25Body weight QTL 253.348body mass (VT:0001259)body weight (CMO:0000012)79324212394811326Rat
2317052Aia17Adjuvant induced arthritis QTL 172.13joint integrity trait (VT:0010548)left rear ankle joint diameter (CMO:0002149)781737938126737938Rat
631529Tls2T-lymphoma susceptibility QTL 200.001thymus integrity trait (VT:0010555)percentage of study population developing T-cell lymphomas during a period of time (CMO:0001911)780221299109401111Rat
1559283Emca4Estrogen-induced mammary cancer QTL 43.7mammary gland integrity trait (VT:0010552)percentage of study population developing mammary tumors during a period of time (CMO:0000948)762004452101773158Rat
1300151Bp181Blood pressure QTL 1813.36arterial blood pressure trait (VT:2000000)diastolic blood pressure (CMO:0000005)753612714103945643Rat
1643004Pain2Pain QTL 21mechanical nociception trait (VT:0002734)self mutilation severity score (CMO:0002145)7946224698011544Rat
1300149Cm6Cardiac mass QTL 64.09heart mass (VT:0007028)heart left ventricle weight to body weight ratio (CMO:0000530)743747099102228765Rat
7411607Foco15Food consumption QTL 150.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)775918751120918751Rat
1558655Swd4Spike wave discharge measurement QTL 43.680.0002brain electrophysiology trait (VT:0010557)brain spike-and-wave discharge severity grade (CMO:0001988)786983365131983365Rat
634336Anxrr17Anxiety related response QTL 173.66locomotor behavior trait (VT:0001392)number of entries into a discrete space in an experimental apparatus (CMO:0000960)7924703115097879Rat
1331768Kidm10Kidney mass QTL 104.62096kidney mass (VT:0002707)left kidney wet weight (CMO:0000083)780221299125221299Rat
1641908Teswt1Testicular weight QTL 13.28testis mass (VT:1000644)both testes wet weight (CMO:0000175)78022129994811326Rat
61357Bp38Blood pressure QTL 381.60.052arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)741333674119109060Rat
2316947Rf58Renal function QTL 587.8kidney glomerulus morphology trait (VT:0005325)index of glomerular damage (CMO:0001135)768938720113886318Rat
724537Niddm52Non-insulin dependent diabetes mellitus QTL 520.02blood glucose amount (VT:0000188)blood glucose level area under curve (AUC) (CMO:0000350)78022129993595843Rat
1298528Bp169Blood pressure QTL 1690.0001arterial blood pressure trait (VT:2000000)systolic blood pressure (CMO:0000004)761074194106074194Rat
1331746Kidm9Kidney mass QTL 93.934kidney mass (VT:0002707)right kidney wet weight (CMO:0000082)780221299112308525Rat
1576303Ept7Estrogen-induced pituitary tumorigenesis QTL 73.7pituitary gland mass (VT:0010496)pituitary gland wet weight (CMO:0000853)762004452101773158Rat
7411654Foco25Food consumption QTL 259.30.001eating behavior trait (VT:0001431)feed conversion ratio (CMO:0001312)775918751120918751Rat
2299163Iddm34Insulin dependent diabetes mellitus QTL 342.71blood glucose amount (VT:0000188)age at onset/diagnosis of type 1 diabetes mellitus (CMO:0001140)791281130135012528Rat
2316955Stl24Serum triglyceride level QTL 247.1blood triglyceride amount (VT:0002644)plasma triglyceride level (CMO:0000548)768938720113886318Rat
2316952Pur22Proteinuria QTL 225.2urine protein amount (VT:0005160)urine protein level (CMO:0000591)768938720113886318Rat
631540Bw9Body weight QTL 94.5body mass (VT:0001259)body weight (CMO:0000012)769736226117455174Rat
1358891Bp265Blood pressure QTL 2652.21arterial blood pressure trait (VT:2000000)mean arterial blood pressure (CMO:0000009)783591953134666232Rat

Markers in Region
D7Kyo1   No map positions available.
D7Wox14  
Rat AssemblyChrPosition (strand)SourceJBrowse
GRCr8795,485,047 - 95,485,178 (+)Marker Load Pipeline
mRatBN7.2793,595,647 - 93,595,780 (+)MAPPERmRatBN7.2
Rnor_6.07102,588,256 - 102,588,387NCBIRnor6.0
Rnor_5.07103,159,395 - 103,159,526UniSTSRnor5.0
RGSC_v3.4798,955,084 - 98,955,215RGDRGSC3.4
RGSC_v3.4798,955,085 - 98,955,215UniSTSRGSC3.4
Celera790,265,846 - 90,265,970UniSTS
RGSC_v3.1798,989,314 - 98,989,445RGD
RH 3.4 Map7654.7UniSTS
RH 3.4 Map7654.7RGD
RH 2.0 Map7541.5RGD
Cytogenetic Map7q33UniSTS
D7Arb5  
Rat AssemblyChrPosition (strand)SourceJBrowse
GRCr8795,485,027 - 95,485,231 (+)Marker Load Pipeline
mRatBN7.2793,595,627 - 93,595,833 (+)MAPPERmRatBN7.2
Rnor_6.07102,588,236 - 102,588,440NCBIRnor6.0
Rnor_5.07103,159,375 - 103,159,579UniSTSRnor5.0
RGSC_v3.4798,955,064 - 98,955,268RGDRGSC3.4
RGSC_v3.4798,955,065 - 98,955,268UniSTSRGSC3.4
Celera790,265,826 - 90,266,023UniSTS
RGSC_v3.1798,989,294 - 98,989,498RGD
Cytogenetic Map7q33UniSTS
D7Wox15  
Rat AssemblyChrPosition (strand)SourceJBrowse
GRCr8795,485,020 - 95,485,179 (+)Marker Load Pipeline
mRatBN7.2793,595,620 - 93,595,781 (+)MAPPERmRatBN7.2
Rnor_6.07102,588,229 - 102,588,388NCBIRnor6.0
Rnor_5.07103,159,368 - 103,159,527UniSTSRnor5.0
RGSC_v3.4798,955,057 - 98,955,216RGDRGSC3.4
RGSC_v3.4798,955,058 - 98,955,216UniSTSRGSC3.4
Celera790,265,819 - 90,265,971UniSTS
RGSC_v3.1798,989,287 - 98,989,446RGD
RH 2.0 Map7544.5RGD
Cytogenetic Map7q33UniSTS
D7Wox29  
Rat AssemblyChrPosition (strand)SourceJBrowse
GRCr8795,485,033 - 95,485,152 (+)Marker Load Pipeline
mRatBN7.2793,595,633 - 93,595,754 (+)MAPPERmRatBN7.2
Rnor_6.07102,588,242 - 102,588,361NCBIRnor6.0
Rnor_5.07103,159,381 - 103,159,500UniSTSRnor5.0
RGSC_v3.4798,955,070 - 98,955,189RGDRGSC3.4
RGSC_v3.4798,955,071 - 98,955,189UniSTSRGSC3.4
Celera790,265,832 - 90,265,944UniSTS
RGSC_v3.1798,989,300 - 98,989,419RGD
RH 2.0 Map7540.1RGD
Cytogenetic Map7q33UniSTS
D7Mit27  
Rat AssemblyChrPosition (strand)SourceJBrowse
GRCr8795,485,031 - 95,485,241 (+)Marker Load Pipeline
mRatBN7.2793,595,631 - 93,595,843 (+)MAPPERmRatBN7.2
Rnor_6.07102,588,240 - 102,588,450NCBIRnor6.0
Rnor_5.07103,159,379 - 103,159,589UniSTSRnor5.0
RGSC_v3.4798,955,068 - 98,955,278RGDRGSC3.4
RGSC_v3.4798,955,069 - 98,955,278UniSTSRGSC3.4
Celera790,265,830 - 90,266,033UniSTS
RGSC_v3.1798,989,298 - 98,989,508RGD
RH 3.4 Map7653.02RGD
RH 3.4 Map7653.02UniSTS
RH 2.0 Map7540.8RGD
Cytogenetic Map7q33UniSTS
RH129446  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2793,598,272 - 93,598,452 (+)MAPPERmRatBN7.2
Rnor_6.07102,590,880 - 102,591,059NCBIRnor6.0
Rnor_5.07103,162,019 - 103,162,198UniSTSRnor5.0
Celera790,268,463 - 90,268,642UniSTS
RH 3.4 Map7654.91UniSTS
Cytogenetic Map7q33UniSTS
D15Mit17  
Rat AssemblyChrPosition (strand)SourceJBrowse
GRCr8795,485,032 - 95,485,179 (+)Marker Load Pipeline
mRatBN7.2793,595,632 - 93,595,781 (+)MAPPERmRatBN7.2
Rnor_6.07102,588,241 - 102,588,388NCBIRnor6.0
Rnor_5.07103,159,380 - 103,159,527UniSTSRnor5.0
RGSC_v3.4798,955,070 - 98,955,216UniSTSRGSC3.4
Celera790,265,831 - 90,265,971UniSTS
Cytogenetic Map7q33UniSTS
PMC156147P1  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2793,595,894 - 93,596,037 (+)MAPPERmRatBN7.2
Rnor_6.07102,588,502 - 102,588,644NCBIRnor6.0
Rnor_5.07103,159,641 - 103,159,783UniSTSRnor5.0
RGSC_v3.4798,955,330 - 98,955,472UniSTSRGSC3.4
Celera790,266,085 - 90,266,227UniSTS
Cytogenetic Map7q33UniSTS
RH94720  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2793,598,438 - 93,598,638 (+)MAPPERmRatBN7.2
Rnor_6.07102,591,046 - 102,591,245NCBIRnor6.0
Rnor_5.07103,162,185 - 103,162,384UniSTSRnor5.0
Celera790,268,629 - 90,268,828UniSTS
Cytogenetic Map7q33UniSTS
PMC165967P4  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2793,592,852 - 93,593,175 (+)MAPPERmRatBN7.2
Rnor_6.07102,585,461 - 102,585,783NCBIRnor6.0
Rnor_5.07103,156,600 - 103,156,922UniSTSRnor5.0
RGSC_v3.4798,952,290 - 98,952,612UniSTSRGSC3.4
Celera790,263,051 - 90,263,373UniSTS
Cytogenetic Map7q33UniSTS
PMC165967P5  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2793,596,195 - 93,596,603 (+)MAPPERmRatBN7.2
Rnor_6.07102,588,803 - 102,589,210NCBIRnor6.0
Rnor_5.07103,159,942 - 103,160,349UniSTSRnor5.0
RGSC_v3.4798,955,631 - 98,956,038UniSTSRGSC3.4
Celera790,266,386 - 90,266,793UniSTS
Cytogenetic Map7q33UniSTS
PMC165967P6  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2793,597,887 - 93,598,317 (+)MAPPERmRatBN7.2
Rnor_6.07102,590,495 - 102,590,924NCBIRnor6.0
Rnor_5.07103,161,634 - 103,162,063UniSTSRnor5.0
RGSC_v3.4798,957,323 - 98,957,752UniSTSRGSC3.4
Celera790,268,078 - 90,268,507UniSTS
Cytogenetic Map7q33UniSTS
PMC148819P4  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2793,597,645 - 93,597,935 (+)MAPPERmRatBN7.2
Rnor_6.07102,590,253 - 102,590,542NCBIRnor6.0
Rnor_5.07103,161,392 - 103,161,681UniSTSRnor5.0
RGSC_v3.4798,957,081 - 98,957,370UniSTSRGSC3.4
Celera790,267,836 - 90,268,125UniSTS
Cytogenetic Map7q33UniSTS
PMC150726P9  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2793,596,003 - 93,596,406 (+)MAPPERmRatBN7.2
Rnor_6.07102,588,611 - 102,589,013NCBIRnor6.0
Rnor_5.07103,159,750 - 103,160,152UniSTSRnor5.0
RGSC_v3.4798,955,439 - 98,955,841UniSTSRGSC3.4
Celera790,266,194 - 90,266,596UniSTS
Cytogenetic Map7q33UniSTS
PMC187450P1  
Rat AssemblyChrPosition (strand)SourceJBrowse
GRCr8795,485,029 - 95,485,501 (+)Marker Load Pipeline
mRatBN7.2793,595,629 - 93,596,103 (+)MAPPERmRatBN7.2
Rnor_6.07102,588,238 - 102,588,710NCBIRnor6.0
Rnor_5.07103,159,377 - 103,159,849UniSTSRnor5.0
RGSC_v3.4798,955,067 - 98,955,538UniSTSRGSC3.4
Celera790,265,828 - 90,266,293UniSTS
Cytogenetic Map7q33UniSTS
G15987  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2793,595,903 - 93,596,024 (+)MAPPERmRatBN7.2
Rnor_6.07102,588,511 - 102,588,631NCBIRnor6.0
Rnor_5.07103,159,650 - 103,159,770UniSTSRnor5.0
RGSC_v3.4798,955,339 - 98,955,459UniSTSRGSC3.4
Celera790,266,094 - 90,266,214UniSTS
Cytogenetic Map7q33UniSTS
MYC  
Rat AssemblyChrPosition (strand)SourceJBrowse
GRCr8795,485,601 - 95,485,804 (+)Marker Load Pipeline
mRatBN7.2793,596,202 - 93,596,406 (+)MAPPERmRatBN7.2
Rnor_6.07102,588,810 - 102,589,013NCBIRnor6.0
Rnor_5.07103,159,949 - 103,160,152UniSTSRnor5.0
RGSC_v3.4798,955,638 - 98,955,841UniSTSRGSC3.4
Celera790,266,393 - 90,266,596UniSTS
Cytogenetic Map7q33UniSTS
Myc  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2793,595,998 - 93,596,278 (+)MAPPERmRatBN7.2
Rnor_6.07102,588,606 - 102,588,885NCBIRnor6.0
Rnor_5.07103,159,745 - 103,160,024UniSTSRnor5.0
RGSC_v3.4798,955,434 - 98,955,713UniSTSRGSC3.4
Celera790,266,189 - 90,266,468UniSTS
Cytogenetic Map7q33UniSTS
MYC  
Rat AssemblyChrPosition (strand)SourceJBrowse
mRatBN7.2793,596,461 - 93,597,750 (+)MAPPERmRatBN7.2
Rnor_6.07102,589,069 - 102,590,357NCBIRnor6.0
Rnor_5.07103,160,208 - 103,161,496UniSTSRnor5.0
RGSC_v3.4798,955,897 - 98,957,185UniSTSRGSC3.4
Celera790,266,652 - 90,267,940UniSTS
Cytogenetic Map7q33UniSTS


Related Rat Strains
The following Strains have been annotated to Myc
W-Tg(MT2A-Myc)1Ys     W-Tg(MT2A-Myc)2Ys    


Expression

RNA-SEQ Expression

alimentary part of gastrointestinal system
appendage
circulatory system
ectoderm
endocrine system
endoderm
exocrine system
hemolymphoid system
hepatobiliary system
integumental system
mesenchyme
mesoderm
musculoskeletal system
nervous system
renal system
reproductive system
respiratory system
sensory system
visual system
16 12 67 162 91 90 59 92 59 6 356 192 11 141 81 92 31 17 17

Sequence


Ensembl Acc Id: ENSRNOT00000006188   ⟹   ENSRNOP00000006188
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8 Ensembl795,483,105 - 95,488,028 (+)Ensembl
mRatBN7.2 Ensembl793,593,705 - 93,598,630 (+)Ensembl
Rnor_6.0 Ensembl7102,586,313 - 102,591,240 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000092876   ⟹   ENSRNOP00000076010
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl7102,588,369 - 102,589,134 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000092908
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.0 Ensembl7102,589,982 - 102,590,741 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000149322   ⟹   ENSRNOP00000108615
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8 Ensembl795,484,895 - 95,488,028 (+)Ensembl
Ensembl Acc Id: ENSRNOT00000149741   ⟹   ENSRNOP00000101493
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8 Ensembl795,483,105 - 95,488,004 (+)Ensembl
RefSeq Acc Id: NM_012603   ⟹   NP_036735
RefSeq Status: REVIEWED
Type: CODING
Position:
Rat AssemblyChrPosition (strand)Source
GRCr8795,483,105 - 95,488,031 (+)NCBI
mRatBN7.2793,593,705 - 93,598,633 (+)NCBI
Rnor_6.07102,586,313 - 102,591,240 (+)NCBI
Rnor_5.07103,157,452 - 103,162,379 (+)NCBI
RGSC_v3.4798,953,142 - 98,958,060 (+)RGD
Celera790,263,903 - 90,268,823 (+)RGD
Sequence:
Protein Sequences
Protein RefSeqs NP_036735 (Get FASTA)   NCBI Sequence Viewer  
GenBank Protein AAH91699 (Get FASTA)   NCBI Sequence Viewer  
  AAQ57167 (Get FASTA)   NCBI Sequence Viewer  
  AAT92511 (Get FASTA)   NCBI Sequence Viewer  
  AAT92512 (Get FASTA)   NCBI Sequence Viewer  
  CAA68459 (Get FASTA)   NCBI Sequence Viewer  
  EDM16184 (Get FASTA)   NCBI Sequence Viewer  
Ensembl Protein ENSRNOP00000006188
GenBank Protein P09416 (Get FASTA)   NCBI Sequence Viewer  
RefSeq Acc Id: NP_036735   ⟸   NM_012603
- UniProtKB: A0A8L2Q2H7 (UniProtKB/Swiss-Prot),   Q6B500 (UniProtKB/Swiss-Prot),   P09416 (UniProtKB/Swiss-Prot),   A0A9H7DMC0 (UniProtKB/TrEMBL)
- Sequence:
Ensembl Acc Id: ENSRNOP00000006188   ⟸   ENSRNOT00000006188
Ensembl Acc Id: ENSRNOP00000076010   ⟸   ENSRNOT00000092876
Ensembl Acc Id: ENSRNOP00000101493   ⟸   ENSRNOT00000149741
Ensembl Acc Id: ENSRNOP00000108615   ⟸   ENSRNOT00000149322
Protein Domains
bHLH

Protein Structures
Name Modeler Protein Id AA Range Protein Structure
AF-P09416-F1-model_v2 AlphaFold P09416 1-439 view protein structure

Transcriptome

eQTL   View at Phenogen
WGCNA   View at Phenogen
Tissue/Strain Expression   View at Phenogen

Promoters
RGD ID:6850240
Promoter ID:EP16061
Type:single initiation site
Name:RN_MYC_1
Description:c-myc (cellular homologue of myelocytomatosis virus 29 oncogene),promoter 1, MYC gene.
SO ACC ID:SO:0000170
Source:EPD (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Notes:homology_group=Homology group 52; Mammalian c-myc proto-oncogene, promoter 1.
Alternative Promoters:alternative promoter #1 of 2; 5' exon 1; site 1.; see alsoEP16062  
Experiment Methods:Nuclease protection
Regulation:(induced by or strongly expressed in) lectin; (induced by or strongly expressed in) PDGF
Position:
Rat AssemblyChrPosition (strand)Source
RGSC_v3.4798,953,142 - 98,953,202EPD
RGD ID:6850258
Promoter ID:EP16062
Type:single initiation site
Name:RN_MYC_2
Description:c-myc (cellular homologue of myelocytomatosis virus 29 oncogene),promoter 2, MYC gene.
SO ACC ID:SO:0000170
Source:EPD (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Notes:homology_group=Homology group 53; Mammalian c-myc proto-oncogene, promoter 2.
Alternative Promoters:alternative promoter #2 of 2; 5' exon 1; site 2; major promoter.; see alsoEP16061  
Experiment Methods:Nuclease protection
Regulation:(induced by or strongly expressed in) lectin; (induced by or strongly expressed in) PDGF
Position:
Rat AssemblyChrPosition (strand)Source
RGSC_v3.4798,953,307 - 98,953,367EPD
RGD ID:13695363
Promoter ID:EPDNEW_R5887
Type:single initiation site
Name:Myc_1
Description:MYC proto-oncogene, bHLH transcription factor
SO ACC ID:SO:0000170
Source:EPDNEW (Eukaryotic Promoter Database, http://epd.vital-it.ch/)
Experiment Methods:Single-end sequencing.
Position:
Rat AssemblyChrPosition (strand)Source
Rnor_6.07102,586,477 - 102,586,537EPDNEW

Additional Information

Database Acc Id Source(s)
AGR Gene RGD:3130 AgrOrtholog
BioCyc Gene G2FUF-33217 BioCyc
Ensembl Genes ENSRNOG00000004500 Ensembl, ENTREZGENE
Ensembl Transcript ENSRNOT00000006188 ENTREZGENE
Gene3D-CATH 4.10.280.10 UniProtKB/Swiss-Prot
IMAGE_CLONE IMAGE:7303974 IMAGE-MGC_LOAD
InterPro bHLH_dom UniProtKB/Swiss-Prot
  HLH_DNA-bd_sf UniProtKB/Swiss-Prot
  Myc-LZ UniProtKB/Swiss-Prot
  Myc_transcription_factors UniProtKB/Swiss-Prot
  Tscrpt_reg_Myc UniProtKB/Swiss-Prot
  Tscrpt_reg_Myc_N UniProtKB/Swiss-Prot
KEGG Report rno:24577 UniProtKB/Swiss-Prot
MGC_CLONE MGC:105490 IMAGE-MGC_LOAD
NCBI Gene 24577 ENTREZGENE
PANTHER MYC PROTO-ONCOGENE UniProtKB/Swiss-Prot
Pfam HLH UniProtKB/Swiss-Prot
  Myc-LZ UniProtKB/Swiss-Prot
  Myc_N UniProtKB/Swiss-Prot
PhenoGen Myc PhenoGen
PIRSF Myc_protein UniProtKB/Swiss-Prot
PRINTS LEUZIPPRMYC UniProtKB/Swiss-Prot
PROSITE BHLH UniProtKB/Swiss-Prot
RatGTEx ENSRNOG00000004500 RatGTEx
SMART HLH UniProtKB/Swiss-Prot
Superfamily-SCOP SSF47459 UniProtKB/Swiss-Prot
TIGR TC231200
UniProt A0A8L2Q2H7 ENTREZGENE
  A0A9H7DMC0 ENTREZGENE, UniProtKB/TrEMBL
  A6HRN8_RAT UniProtKB/TrEMBL
  MYC_RAT UniProtKB/Swiss-Prot, ENTREZGENE
  Q6B500 ENTREZGENE
UniProt Secondary A0A8L2Q2H7 UniProtKB/Swiss-Prot
  Q6B500 UniProtKB/Swiss-Prot


Nomenclature History
Date Current Symbol Current Name Previous Symbol Previous Name Description Reference Status
2017-03-29 Myc  MYC proto-oncogene, bHLH transcription factor  Myc  myelocytomatosis oncogene  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2008-02-13 Myc  myelocytomatosis oncogene  Myc  myelocytomatosis viral oncogene homolog (avian)  Nomenclature updated to reflect human and mouse nomenclature 1299863 APPROVED
2004-12-14 Myc  myelocytomatosis viral oncogene homolog (avian)    v-myc avian myelocytomatosis viral oncogene homolog   Name updated 1299863 APPROVED
2002-06-10 Myc  v-myc avian myelocytomatosis viral oncogene homolog       Name updated 70585 PROVISIONAL

RGD Curation Notes
Note Type Note Reference
gene_drugs mRNA degradation is stopped by the inhibition of protein synthesis by cycloheximide which results in the accumalation os mRNA in various cells 69897
gene_drugs mRNA degradation is stopped by the inhibition of protein synthesis by cycloheximide which results in the accumalation os mRNA in various cells 70227
gene_function binds to DNA 70227
gene_function binds to DNA 625485
gene_function binds to TFIIIB, a pol III-specific general transcription factor 729124
gene_mutations_overexpression overexpression or deregulation causes unlimited growth of the cancer cells 69897
gene_mutations_overexpression overexpression or deregulation causes unlimited growth of the cancer cells 70227
gene_process may repress transcription of target genes of the apopototic pathway which leads to cell death following DNA damage 625509
gene_process has a role in growth competence, differentiation, and apoptosis 70227
gene_process has a role in growth competence, differentiation, and apoptosis 625485
gene_process plays a role in beta-cell de-differentiation 70227
gene_process plays a role in beta-cell de-differentiation 625485
gene_regulation expression in beta-cells increased by cytokines such as interleukin1-beta and interferon-gamma, this is prevented by blocking NF-kappaB activation but not by an iNO blocker 69897
gene_regulation expression in beta-cells increased by cytokines such as interleukin1-beta and interferon-gamma, this is prevented by blocking NF-kappaB activation but not by an iNO blocker 70227